Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Cardiology/Vascular Diseases
Clinical Trials: Atrial Fibrillation
A listing of clinical trials currently looking for volunteers to enroll in Atrial Fibrillation studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : University of Alabama at Birmingham Updated
Clarification of Optimal Anticoagulation Through Genetics
Birmingham : University of Alabama at Birmingham
Does Atorvastatin Prevent Post Operative Atrial Fibrillation After Pulmonary Resection: A Randomized Clinical Study
Birminham : University of Alabama, Birmingham
Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)
Mobile : 1160.128.1003 Boehringer Ingelheim Investigational Site
A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
Arizona
Gilbert : Mercy Gilbert Medical Center
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Phoenix : Investigational Site
A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)
Phoenix :
BIOTRONIK IMPACT Study
Scottsdale :
BIOTRONIK IMPACT Study
Scottsdale : Arizona Heart Rhythm Research Center
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Arkansas
Little Rock : Arkansas Cardiology, PA
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
California
Santa Ana : Coastal Multi-Specialty Research
Cardiovascular outcomes study to evaluate the potential to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event & type II diabetes mellitus.
Santa Ana : Coastal Multi-Specialty Research
Patients who have Type II diabetes & coronary artery disease, post angiogram or heart attack. This is a phase 3b study. Currently open for enrollment.
Santa Ana : Coastal Multi-Specialty Research
RESCUE cardiovascular clinical trial
View More »
Anaheim :
BIOTRONIK IMPACT Study
Beverly Hills : Investigational Site
A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)
Fremont :
BIOTRONIK IMPACT Study
Fresno : St. Agnes Medical Center
CONcomitant eValuation of Epicor Left atRial Therapy for AF
La Jolla : Foundation for Cardiovascular Medicine
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
La Jolla : Scripps Green
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Los Angeles : Ronald Reagan UCLA Medical Center
ABLATE AF Registry Trial
Los Angeles : Cedars-Sinai Medical Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Los Angeles : Good Samaritan Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Los Angeles : Hollywood Heart and Vascular Research Institute
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Los Angeles : Cedars-Sinai Medical Center
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Los Angeles : Good Samaritan Hospital
Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)
Mountain View : El Camino Hospital
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Orange : Orange County Heart Institute and Research Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Orange County : Orange County Heart
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Palo Alto : Stanford Hospital
Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)
Redwood City : Sequoia Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Sacramento : Investigational Site
A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)
Sacramento : University of California Davis Medical Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Sacramento : Regional Cardiology Associates
Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation
Sacramento : UC Davis Medical Center
Ventricular Rate Regularization for Improved Quality of Life in Patients With CHF and AF
San Diego : University of California San Diego Medical Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
San Francisco : University of California at San Francisco Medical Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
San Francisco : University of California San Francisco Updated
Clarification of Optimal Anticoagulation Through Genetics
Santa Barbara :
BIOTRONIK IMPACT Study
Santa Monica : St. John's Hospital / Pacific Heart
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Stanford : Stanford University Medical Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Stanford : Stanford Univeristy Medical Center
Use of the Hansen Medical System in Patients With Atrial Fibrillation
Tarzana : Heart Rythm Specialists of Southern California
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Torrance :
BIOTRONIK IMPACT Study
Ventura :
BIOTRONIK IMPACT Study
Colorado
Aurora :
BIOTRONIK IMPACT Study
Aurora : The Medical Center of Aurora
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Boulder :
BIOTRONIK IMPACT Study
Colorado Spring : 1160.128.1005 Boehringer Ingelheim Investigational Site
A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
Colorado Springs : Penrose Saint Francis Health Services
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
View More »
Denver : 1160.128.1023 Boehringer Ingelheim Investigational Site
A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
Denver : South Denver Cardiology / Swedish Medical Center
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Connecticut
Guilford : 1160.128.1018 Boehringer Ingelheim Investigational Site
A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
Hartford : Hartford Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Delaware
Newark :
BIOTRONIK IMPACT Study
Florida
Atlantis : Palm Beach Heart Research
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Bradenton : Manatee Memorial Hospital
CONcomitant eValuation of Epicor Left atRial Therapy for AF
Brandon : 1160.128.1032 Boehringer Ingelheim Investigational Site
A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
Davenport :
BIOTRONIK IMPACT Study
Daytona Beach : 1160.128.1027 Boehringer Ingelheim Investigational Site
A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
View More »
Daytona Beach :
BIOTRONIK IMPACT Study
Gainesville : University of Florida - Shands Hospital
ABLATE AF Registry Trial
Gainesville : University of Florida Updated
Clarification of Optimal Anticoagulation Through Genetics
Gainesville : University of Florida
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Jacksonville : Diagnostic Cardiology Associates PA
NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation
Kissimmee :
BIOTRONIK IMPACT Study
Melbourne :
BIOTRONIK IMPACT Study
Miami : Baptist Hospital of Miami
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Orlando : Florida Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Orlando : Florida Hospital
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Port Charlotte : 1160.128.1007 Boehringer Ingelheim Investigational Site
A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
Sarasota : Otsuka Investigational Site
Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation
Sarasota :
BIOTRONIK IMPACT Study
St. Petersburg :
BIOTRONIK IMPACT Study
Tallahassee : Tallahassee Memorial Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Tampa : Pepin Heart Hospital
ABLATE AF Registry Trial
Tampa : Florida Heart Rhythm-University of South Florida College of Medicine
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Venice : Venice Regional Medical Center
nContactSurgical Numeris-AF Tethered Coagulation System for Treatment of Longstanding Persistent Atrial Fibrillation (AF)
Zephyrhills :
BIOTRONIK IMPACT Study
Georgia
Savannah : Memorial Health University Medical Center
Global Study to Assess the Safety and Effectiveness of DU-176b vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation (EngageAFTIMI48)
Savannah : Memorial Health University Medical Center
Global Study to Assess the Safety and Effectiveness of DU-176b vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation (EngageAFTIMI48)
View More »
Atlanta : Saint Joseph's Hospital of Atlanta
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Atlanta : Emory University
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Atlanta : Emory University Hospital Midtown
Management of New-Onset Postoperative Atrial Fibrillation
Augusta : Georgia Health Sciences University
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Augusta : Georgia Health Sciences University Updated
Clarification of Optimal Anticoagulation Through Genetics
Macon : Georgia Arrhythmia Consultants & Research Institute
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Illinois
Barrington : Alexian Brothers Medical Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Chicago :
BIOTRONIK IMPACT Study
Chicago : Northwestern Memorial Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Chicago : Rush University Medical Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Chicago : Northwestern Memorial Hospital
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
View More »
Chicago : Rush University Medical Center
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Elk Grove Village :
BIOTRONIK IMPACT Study
Evanston : NorthShore University Health System
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Evanston : NorthShore University Health System
CONcomitant eValuation of Epicor Left atRial Therapy for AF
Evanston : North Shore University
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Maywood :
BIOTRONIK IMPACT Study
Maywood : Loyola University Medical Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Maywood : Loyola University Medical Center
NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation
Springfield : Prairie Heart Institute
Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)
Indiana
Fort Wayne :
BIOTRONIK IMPACT Study
Indianapolis : 1160.128.1029 Boehringer Ingelheim Investigational Site
A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
Indianapolis : Heart Center of Indiana
ABLATE AF Registry Trial
Indianapolis : St. Francis Heart Center
ABLATE AF Registry Trial
Indianapolis : Indiana University Medical Center, School of Medicine
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
View More »
Indianapolis : Saint Vincent Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Muncie : Medical Consultants, P.C.
Ibutilide Administration During Pulmonary Vein Ablation
Munster : Community Hospital
CONcomitant eValuation of Epicor Left atRial Therapy for AF
Valparaiso :
BIOTRONIK IMPACT Study
Iowa
Des Moines : Iowa Heart Center
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Des Moines : Iowa Heart / Ruan Neurology
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
West Des Moines : Mercy Medical Center-Iowa Heart Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Kansas
Kansas City : The University of Kansas Medical Center
Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)
Shawnee Mission :
BIOTRONIK IMPACT Study
Kentucky
Greenville : Greenville Hospital System Cardiology/Cardiovascular Research
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Lexington :
BIOTRONIK IMPACT Study
Lexington : Central Baptist Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Lexington : Central Baptist Hospital
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Lexington : Central Baptist Hospital
NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation
View More »
Louisville :
BIOTRONIK IMPACT Study
Louisville : Louisville Cardiology
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Owensboro :
BIOTRONIK IMPACT Study
Louisiana
Hammond :
BIOTRONIK IMPACT Study
Lafayette :
BIOTRONIK IMPACT Study
New Orleans :
BIOTRONIK IMPACT Study
New Orleans : Tulane University Health Science Center Updated
Clarification of Optimal Anticoagulation Through Genetics
Maine
Auburn : 1160.128.1025 Boehringer Ingelheim Investigational Site
A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
Bangor :
BIOTRONIK IMPACT Study
Lewiston :
BIOTRONIK IMPACT Study
Maryland
Baltimore : Johns Hopkins Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Baltimore : University of Maryland School of Medicine Updated
Clarification of Optimal Anticoagulation Through Genetics
Baltimore : Midatlanatic Cardiovascular Associates, PA; Union Memorial Hospital
CONcomitant eValuation of Epicor Left atRial Therapy for AF
Baltimore : University of Maryland
NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation
Baltimore : Johns Hopkins Hospital
NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation
View More »
Cumberland :
BIOTRONIK IMPACT Study
Salisbury : 1160.128.1012 Boehringer Ingelheim Investigational Site
A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
Silver Spring : Washington Adventist Hospital
NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation
Massachusetts
Boston :
BIOTRONIK IMPACT Study
Boston : Brigham and Womens Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Boston : Massachusetts General Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Boston : Brigham and Women's Hospital
Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation
Boston : Beth Israel Deaconess Medical Center
NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation
View More »
Boston : Brigham and Women's Hospital
NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation
Burlington :
BIOTRONIK IMPACT Study
Burlington : Lahey Clinic
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Worcester : Otsuka Investigational Site
Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation
Worcester :
BIOTRONIK IMPACT Study
Michigan
Ann Arbor :
BIOTRONIK IMPACT Study
Ann Arbor : University of Michigan Cardiovascular Center
Effects of Fish Oil on Post Ablation Arrhythmias
Bay City :
BIOTRONIK IMPACT Study
Detroit : Henry Ford Hospital Updated
Clarification of Optimal Anticoagulation Through Genetics
Grand Rapids : Spectrum Health
ABLATE AF Registry Trial
View More »
Lansing : Thoracic & Cardiovascular Healthcare Foundation
ABLATE AF Registry Trial
Lansing :
BIOTRONIK IMPACT Study
Lapeer :
BIOTRONIK IMPACT Study
Rochester Hills : 1160.128.1015 Boehringer Ingelheim Investigational Site
A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
Royal Oak : William Beaumont Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Royal Oak : William Beaumont Hospital
CONcomitant eValuation of Epicor Left atRial Therapy for AF
Royal Oak : William Beaumont
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Royal Oak : Beaumont Hospital
Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)
Royal Oak : William Beaumont Hospital
Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery
Saginaw :
BIOTRONIK IMPACT Study
Traverse City : Munson Medical Center
ABLATE AF Registry Trial
Troy : William Beaumont Hospital
Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery
Ypsilanti :
BIOTRONIK IMPACT Study
Ypsilanti : Saint Joseph Mercy Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Minnesota
Minneapolis :
BIOTRONIK IMPACT Study
Minneapolis : Minneapolis V.A. Medical Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Minneapolis : University of Minnesota
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Minneapolis : Minneapolis Heart Institute Foundation/Abbott NW Hospital
CONcomitant eValuation of Epicor Left atRial Therapy for AF
Minneapolis : Abbott Northwestern Hospital
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
View More »
Minneapolis : Park Nicollet Institute
NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation
Rochester : Mayo Clinic Rochester
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Rochester : Mayo Clinic College of Medicine Updated
Clarification of Optimal Anticoagulation Through Genetics
Rochester : Mayo Clinic
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
St. Louis Park : Park Nicollet Methodist Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
St. Paul : Saint Joseph's Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
St. Paul : United Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Mississippi
Tupelo : 1160.128.1004 Boehringer Ingelheim Investigational Site
A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
Tupelo :
BIOTRONIK IMPACT Study
Tupelo : Cardiology Associates of N. Mississippi
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Tupelo : Cardiology Associates Research, LLC
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Missouri
Columbia : 1160.128.1014 Boehringer Ingelheim Investigational Site
A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
Kansas City :
BIOTRONIK IMPACT Study
Kansas City : St. Luke's Hospital
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Kansas City : Mid America Heart Institute / St. Lukes Hospital
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Osage Beach :
BIOTRONIK IMPACT Study
View More »
St. Louis : Washington University/Barnes Jewish Hospital
ABLATE AF Registry Trial
St. Louis :
BIOTRONIK IMPACT Study
St. Louis : Saint John's Mercy Heart Health Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
St. Louis : Washington University School of Medicine Updated
Clarification of Optimal Anticoagulation Through Genetics
St. Louis : St. John's Mercy
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
St. Louis : Washington University Medical School
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Montana
Kalispell : 1160.128.1011 Boehringer Ingelheim Investigational Site
A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
Missoula : The International Heart Institute of Montana
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Nebraska
Lincoln : Nebraska Heart Hospital
ABLATE AF Registry Trial
Lincoln : Bryan LGH
Determination of Rates and Reasons for Non-Adherence to Anti-Arrhythmic Therapy for Atrial Fibrillation
Lincoln : Bryan LGH
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Omaha :
BIOTRONIK IMPACT Study
Omaha : Alegent Health Bergan Mercy Medical Center
Determination of Rates and Reasons for Non-Adherence to Anti-Arrhythmic Therapy for Atrial Fibrillation
View More »
Omaha : Creighton University
Determination of Rates and Reasons for Non-Adherence to Anti-Arrhythmic Therapy for Atrial Fibrillation
Nevada
Henderson : Cardiovascular Consultants of Nevada
Safety of Amiodarone and Ranolazine Together in Patients With Angina
Las Vegas : Cardiovascular Consultants of Nevada
Safety of Amiodarone and Ranolazine Together in Patients With Angina
New Jersey
Camden : Cooper University Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Camden : Cooper University Hospital
CONcomitant eValuation of Epicor Left atRial Therapy for AF
Englewood : Englewood Hospital and Medical Center
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Hackensack : Hackensack University Medical Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Hackensack : Hackensack University Medical Center
CONcomitant eValuation of Epicor Left atRial Therapy for AF
View More »
Hackensack : Hackensack University Medical Center
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
News Brunswick : Robert Wood Johnson University Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Ridgewood :
BIOTRONIK IMPACT Study
Ridgewood : Valley Health System
Catheter Ablation for Recently Diagnosed Paroxysmal Atrial Fibrillation
New York
New York : Biomedical Research Alliance of New York
Paroxysmal Atrial Fibrillation (PAF)
View More »
Albany : Albany Associates in Cardiology
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Bronx : Montefiore Medical Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Bronx : Montefiore Medical Center Updated
Clarification of Optimal Anticoagulation Through Genetics
New York :
BIOTRONIK IMPACT Study
New York : New York University Langone Medical Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
New York : Columbia University Medical Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
New York : Mount Sinai School of Medicine
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
New York : Saint Lukes-Roosevelt Hospital Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
New York : Mount Sinai School of Medicine Updated
Clarification of Optimal Anticoagulation Through Genetics
New York : Mount Sinai School of Medicine
Deviating the Esophagus in Atrial Fibrillation Ablation
New York : Mt. Sinai School of Medicine
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
New York : New York University Medical Center
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
New York : Mount Sinai School of Medicine
Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation
New York : St. Luke's Roosevelt Hospital
NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation
New York :
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
New York : Mount Sinai Medical Center
TOCCASTAR - TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation
NY : Mt. Sinai Hospital
Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)
Poughkeepsie : 1160.128.1001 Boehringer Ingelheim Investigational Site
A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
Rochester : Investigational Site
A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)
Rochester : University of Rochester Medical Center
CONcomitant eValuation of Epicor Left atRial Therapy for AF
Rochester : University of Rochester Medical Center
NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation
Roslyn : St. Francis Hospital
CONcomitant eValuation of Epicor Left atRial Therapy for AF
Staten Island : Staten Island University Hosptial
Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation
Stony Brook : Stony Brook University Hospital and Medical Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Stony Brook : Stony Brook Univeristy Medical Center
Use of the Hansen Medical System in Patients With Atrial Fibrillation
Utica : Investigational Site
A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)
North Carolina
Ashebille : 1160.128.1022 Boehringer Ingelheim Investigational Site
A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
Asheville : Mission Hospital, Inc
CONcomitant eValuation of Epicor Left atRial Therapy for AF
Chapel Hill : University of North Carolina at Chapel Hill
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Charlotte : The Sanger Clinic, PA
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Charlotte : Carolinas Medical Center
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
View More »
Durham :
BIOTRONIK IMPACT Study
Durham : Duke University Medical Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Durham : Duke University Updated
Clarification of Optimal Anticoagulation Through Genetics
Durham : Duke University Medical Center
CONcomitant eValuation of Epicor Left atRial Therapy for AF
Durham : Duke University Medical Center
NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation
Hickory :
BIOTRONIK IMPACT Study
Winston-Salem : Wake Forest University Health Sciences
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Winston-Salem : Forsyth Medical Center
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Ohio
Cincinnati : Good Samaritan Hospital
ABLATE AF Registry Trial
Cincinnati :
BIOTRONIK IMPACT Study
Cincinnati : Cardiology Center of Cincinnati
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Cincinnati : Medisync
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Cincinnati : University of Cincinnati Medical Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
View More »
Cincinnati : Lindner Clinical Trial Center
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Cleveland :
BIOTRONIK IMPACT Study
Cleveland : Cleveland Clinic
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Cleveland : University Hospital of Cleveland
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Cleveland : Cleveland Clinic
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Cleveland : Cleveland Clinic Foundation
NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation
Cleveland : Cleveland Clinic
Siemens 3-D C-Arm CT of the Heart Chambers
Columbus : Investigational Site
A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)
Columbus : Ohio State University Medical Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Columbus : Ohio State University
NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation
Columbus : Ohio Health Research
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Kettering :
BIOTRONIK IMPACT Study
Middletown :
BIOTRONIK IMPACT Study
Toledo :
BIOTRONIK IMPACT Study
Toledo : University of Toledo
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Westlake :
BIOTRONIK IMPACT Study
Oklahoma
Oklahoma City : Oklahoma Heart Hospital
ABLATE AF Registry Trial
Oklahoma City :
BIOTRONIK IMPACT Study
Oklahoma City : University of Oklahoma
NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation
Oklahoma City : OU Medical Center
Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardioversion
Tulsa :
BIOTRONIK IMPACT Study
View More »
Tulsa : Oklahoma Heart Institute
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Oregon
Eugene : Sacred Heart Medical Center
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Hillsboro : 1160.128.1033 Boehringer Ingelheim Investigational Site
A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
Portland : Providence Saint Vincent Medical Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Portland : Oregon Health and Science University
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Portland : Providence Heart and Vascular Institute
nContactSurgical Numeris-AF Tethered Coagulation System for Treatment of Longstanding Persistent Atrial Fibrillation (AF)
View More »
Tualatin :
BIOTRONIK IMPACT Study
Pennsylvania
Abington :
BIOTRONIK IMPACT Study
Altoona : 1160.128.1037 Boehringer Ingelheim Investigational Site
A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
Camp Hill : 1160.128.1034 Boehringer Ingelheim Investigational Site
A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
Danville : Geisinger Wyoming Valley Medical Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Doylestown : Central Bucks Specialists-Doylestown Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
View More »
Doylestown :
Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure
Doylestown : Central Bucks Specialists / Doylestown Hospital
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Harrisburg : Pinnacle Health
ABLATE AF Registry Trial
Hershey : Penn State University Cardiovascular Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Langhorne : 1160.128.1010 Boehringer Ingelheim Investigational Site
A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
North Wales : Call for Information
Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)
Philadelphia : University of Pennsylvania
Assessing Arrhythmias After Ablation Using Implantable Recorders
Philadelphia :
BIOTRONIK IMPACT Study
Philadelphia : Drexel University College of Medicine
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Philadelphia : University of Pennsylvania Health System
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Philadelphia : Hospital of the University of Pennsylvania Updated
Clarification of Optimal Anticoagulation Through Genetics
Philadelphia : Hospital of the University of Pennsylvania
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Philadelphia : Hospital of the University of Pennsylvania
Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation
Philadelphia : Hospital of the University of Pennsylvania
NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation
Philadelphia : Thomas Jefferson University
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Phoenixville :
BIOTRONIK IMPACT Study
Pittsburgh :
BIOTRONIK IMPACT Study
Pittsburgh : V.A. Pittsburgh Healthcare System
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Pittsburgh : University of Pittsburgh Medical Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Wormleysburg : Moffitt Heart & Vascular
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Wynnewood : Lankenau Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
South Carolina
Mt Pleasant : PMG Research of Charleston
ATRIAL FIBRILLATION: Have you been diagnosed with Atrial Fibrillation in the last year?
View More »
Charleston : Investigational Site
A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)
Charleston : Medical University of South Carolina
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Greenville :
BIOTRONIK IMPACT Study
Greenville : Greenville Hospital System
Use of the Hansen Medical System in Patients With Atrial Fibrillation
Rock Hill :
BIOTRONIK IMPACT Study
Tennessee
Chattanooga : Memorial Health Care System
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Cookeville :
BIOTRONIK IMPACT Study
Germantown :
BIOTRONIK IMPACT Study
Memphis : Baptist Memorial Hospital
nContactSurgical Numeris-AF Tethered Coagulation System for Treatment of Longstanding Persistent Atrial Fibrillation (AF)
Nashville :
BIOTRONIK IMPACT Study
View More »
Nashville : Vanderbilt University Medical Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Nashville : Vanderbilt University Updated
Clarification of Optimal Anticoagulation Through Genetics
Nashville : Vanderbilt Medical School
Evaluating the Effectiveness of Fish Oil Supplements at Reducing the Recurrence of Atrial Fibrillation
Nashville : St. Thomas Research Institute
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Nashville : St. Thomas Research Institute
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Texas
Houston : DM Clinical Research
Atrial Fibrillation - Houston, TX
View More »
Austin : Texas Cardiac Arrhythmia
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Austin : Texas Cardiac Arrhythmia
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Austin : Austin Heart PA
NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation
Austin : Texas Cardiac Arrhythmia Research Foundation
Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)
Austin : Texas Cardiac Arrhythmia Research Foundation (TCARF)
Use of the Hansen Medical System in Patients With Atrial Fibrillation
Corpus Christi :
BIOTRONIK IMPACT Study
Dallas : Baylor Heart and Vascular Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Dallas : Baylor Research Institute
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Dallas : Baylor Research Institute
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Dallas : University of Texas - Southwestern Medical Center
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Fort Worth : Baylor All Saints Medical Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Galveston : University of Texas Medical Branch Updated
Clarification of Optimal Anticoagulation Through Genetics
Houston : Otsuka Investigational Site
Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation
Houston :
BIOTRONIK IMPACT Study
Houston : University of Texas Health Science Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Houston : Texas Heart Institute at St. Luke's Episcopal Hospital
CONcomitant eValuation of Epicor Left atRial Therapy for AF
Houston : Methodist Hospital
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Houston : Houston Methodist
Use of the Hansen Medical System in Patients With Atrial Fibrillation
Humble :
BIOTRONIK IMPACT Study
Killeen : 1160.128.1006 Boehringer Ingelheim Investigational Site
A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
Kingwood :
BIOTRONIK IMPACT Study
Plano : The Heart Hospital Baylor Plano
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
San Antonio : South Texas Cardiovascular Consultants
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Temple : Scott and White Memorial Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Utah
Murray : Intermountain Medical Center Updated
Clarification of Optimal Anticoagulation Through Genetics
Murray : Intermountain Medical Center
Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)
Ogden : McKay-Dee Hospital Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Provo : Utah Valley Regional Medical Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Salt Lake City : St. Mark's
ABLATE AF Registry Trial
View More »
Salt Lake City : Intermountain Medical Center-LDS Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Salt Lake City : University of Utah Health Care Updated
Clarification of Optimal Anticoagulation Through Genetics
Salt Lake City : Intermountain Medical Center
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Vermont
Burlington : Fletcher Allen
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Virginia
Charlottesville : University of Virginia Health System
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Charlottesville : University Of Virginia Health System
Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation
Charlotteville : Univeristy of Virginia
Use of the Hansen Medical System in Patients With Atrial Fibrillation
Fairfax : Virginia Hospital Center - Arlington
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Fairfax : Inova Fairfax Hospital
NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation
View More »
Falls Church : Inova Fairfax Hospital
CONcomitant eValuation of Epicor Left atRial Therapy for AF
Norfolk : Sentara Norfolk General Hospital
ABLATE AF Registry Trial
Norfolk : Sentara Norfolk General Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Norfolk : Sentara Cardiovascular Research Institute
Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)
Richmond : University of Virginia Commonwealth/Medical College of Virginia
ABLATE AF Registry Trial
Richmond : Virginia Commonwealth University Medical Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Richmond : Virginia Commonwealth University
NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation
Washington
Seattle : Swedish Medical Center
ABLATE AF Registry Trial
Seattle : University of Washington Medical Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Seattle : Swedish Medical Center - Providence Campus
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Seattle : Swedish Medical Center
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Tacoma : Cardiac Study Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Wisconsin
Madison : Investigational Site
A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)
Marshfield : St. Josephs Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Marshfield : Marshfield Clinical Research Foundation Updated
Clarification of Optimal Anticoagulation Through Genetics
Milwaukee : Aurora Saint Lukes Medical Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Milwaukee : St. Luke's Hospital
Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
View More »
Milwaukee : St. Luke's Medical Center
NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation
Wausau : Aspirus Wausau Hospital
ABLATE AF Registry Trial
Australia
Adelaide : Royal Adelaide Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Adelaide : Royal Adelaide Hospital
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
Brisbane : St. Andrews War Memorial Hospital
Substrate and Trigger Ablation for Reduction of Atrial Fibrillation Trial - Star AF II Study
Greenslopes : Greenslopes Private Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Herston : Royal Brisbane and Women's Hospital
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
View More »
Parkville : Royal Adelaide Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Parkville : Royal Melbourne Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Perth : Royal Perth Hospital Updated
ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial
Wahroonga :
BIOTRONIK IMPACT Study
Westworthville : Westmead Hospital
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
Woolloongabba : Princess Alexandra Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Austria
Graz : LKH/Uniklinikum - Klinische Abteilung für Kardiologie Updated
Graz Study on the Risk of Atrial Fibrillation
Graz : Marianne Brodmann
Prospective, Multi Centre, International Registry of Male and Female Patients Newly Diagnosed With Atrial Fibrillation
Graz : LKH Universitätsklinikum Graz
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Linz : KH d. Elisabethinen Linz GmbH Updated
ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial
Linz : A. ö. Krankenhaus der Elisabethinen Linz
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
View More »
Tulln : Landesklinikum Donauregion Tulln
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Wien : Allgemeines Krankenhaus der Stadt Wien
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
Belgium
Antwerp : UZ Antwerpen
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Antwerpen : A.Z. Middelheim
Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)
Brugge : A.Z. St Jan AV
Atrial Fibrillation Progression Trial
Brugge : AZ St. Jan
Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)
Brugge : AZ St Jan, Cardiologie
REVOLUTION (WFCC-133)
View More »
Bruxelles : Cliniques universitaires Saint-Luc Updated
ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial
Leuven : UZ Leuven
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Yvoir : Cliniques Universitaires UCL Mont-Godinne
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Brazil
Sao Paulo : Merck Sharp & Dohme Farmaceutica Ltda.
International Registry on Cardioversion of Atrial Fibrillation (MK-6621-051)
Canada
Antigonish : 1160.129.06010 Boehringer Ingelheim Investigational Site
GLORIA-AF Registry Program - Second and Third Phases
Calgary : Foothills Medical Center Updated
ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial
Calgary : University of Calgary
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Calgary : 1160.129.06018 Boehringer Ingelheim Investigational Site
GLORIA-AF Registry Program - Second and Third Phases
Calgary : University of Calgary, Foothills Hospital
Paroxysmal Atrial Fibrillation: Role of Inflammation, Oxidative Stress Injury and Effect of Statins
View More »
Cambridge : 1160.129.06023 Boehringer Ingelheim Investigational Site
GLORIA-AF Registry Program - Second and Third Phases
Chicoutimi : 1160.129.06024 Boehringer Ingelheim Investigational Site
GLORIA-AF Registry Program - Second and Third Phases
Coquitlam : 1160.129.06005 Boehringer Ingelheim Investigational Site
GLORIA-AF Registry Program - Second and Third Phases
Downsview : 1160.129.06003 Boehringer Ingelheim Investigational Site
GLORIA-AF Registry Program - Second and Third Phases
Edmonton : 1160.129.06004 Boehringer Ingelheim Investigational Site
GLORIA-AF Registry Program - Second and Third Phases
Grimsby : 1160.129.06020 Boehringer Ingelheim Investigational Site
GLORIA-AF Registry Program - Second and Third Phases
Halifax : QE II Health Sciences Center Updated
ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial
Halifax : 1160.129.06025 Boehringer Ingelheim Investigational Site
GLORIA-AF Registry Program - Second and Third Phases
Hamilton : McMaster University and Hamilton Health Sciences Updated
ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial
Hamilton : Hamilton Health Sciences/McMaster University
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Hamilton : 1160.129.06016 Boehringer Ingelheim Investigational Site
GLORIA-AF Registry Program - Second and Third Phases
Hamilton : 1160.129.06032 Boehringer Ingelheim Investigational Site
GLORIA-AF Registry Program - Second and Third Phases
Hamilton : Hamilton Health Sciences / Hamilton General Hospital
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Kelowna : 1160.129.06027 Boehringer Ingelheim Investigational Site
GLORIA-AF Registry Program - Second and Third Phases
Kingston : Kingston General Hospital
Incidence of Atrial Fibrillation in Patients With Severe Obstructive Sleep Apnea: The Reveal XT-SA Study
Levis : 1160.129.06014 Boehringer Ingelheim Investigational Site
GLORIA-AF Registry Program - Second and Third Phases
London : London Health Science Centers Updated
ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial
London : University of Western Ontario-London Health Sciences Centre
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
London : London Health Services Center
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
MIssissauga : 1160.129.06028 Boehringer Ingelheim Investigational Site
GLORIA-AF Registry Program - Second and Third Phases
Montreal : Montreal General Hospital Updated
ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial
Montreal : Montreal Heart Institute Updated
ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial
Montreal :
BIOTRONIK IMPACT Study
Montreal : 1160.129.06009 Boehringer Ingelheim Investigational Site
GLORIA-AF Registry Program - Second and Third Phases
Montreal : Montreal Heart Institute (Institut de Cardiologie de Montreal)
NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation
Newmarket : Southlake Regional Health Center Updated
ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial
Newmarket : Southlake Regional Health Centre
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Newmarket : Southlake Regional Health Centre
Efficiency Study Evaluating the Use of the PVAC Catheter Technology for Performing Ablation in Patients With Atrial Fibrillation
Newmarket : Southlake Regional Health Centre
GENESIS Feasibility Study of the BARD Over-the-Wire Mesh Ablation System for the Treatment of Paroxysmal Atrial Fibrillation
Newmarket : Southlake Regional Health Centre
Substrate and Trigger Ablation for Reduction of Atrial Fibrillation Trial - Star AF II Study
Oakville : 1160.129.06017 Boehringer Ingelheim Investigational Site
GLORIA-AF Registry Program - Second and Third Phases
Oshawa : 1160.129.06001 Boehringer Ingelheim Investigational Site
GLORIA-AF Registry Program - Second and Third Phases
Ottawa : Ottawa Heart Institute Updated
ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial
Ottawa : 1160.129.06013 Boehringer Ingelheim Investigational Site
GLORIA-AF Registry Program - Second and Third Phases
Quebec : Institut universitaire de cardiologie et de pneumologie de Québec Updated
ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial
Québec : 1160.129.06006 Boehringer Ingelheim Investigational Site
GLORIA-AF Registry Program - Second and Third Phases
Richmond : 1160.129.06034 Boehringer Ingelheim Investigational Site
GLORIA-AF Registry Program - Second and Third Phases
Sainte-Foy : 1160.129.06022 Boehringer Ingelheim Investigational Site
GLORIA-AF Registry Program - Second and Third Phases
Saskatoon : 1160.129.06002 Boehringer Ingelheim Investigational Site
GLORIA-AF Registry Program - Second and Third Phases
Sherbrooke : Centre hospitalier universitaire de Sherbrooke Updated
ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial
Sherbrooke :
BIOTRONIK IMPACT Study
Sherbrooke : CHUS / Hopital Fleurimont
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
St. John's : 1160.129.06007 Boehringer Ingelheim Investigational Site
GLORIA-AF Registry Program - Second and Third Phases
St-Jean-sur-Richel : 1160.129.06030 Boehringer Ingelheim Investigational Site
GLORIA-AF Registry Program - Second and Third Phases
Toronto : 1160.129.06026 Boehringer Ingelheim Investigational Site
GLORIA-AF Registry Program - Second and Third Phases
Toronto : 1160.129.06029 Boehringer Ingelheim Investigational Site
GLORIA-AF Registry Program - Second and Third Phases
Toronto : Sunnybrook Health Sciences Centre
Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation
Vancouver : Royal Jubilee Hospital Updated
ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial
Vancouver : Saint Pauls Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Vancouver : St. Paul's Hospital
Measurement of Left and Right Atria From CT Scans of Cardiac Rhythm Disorder Cases
Victoria : 1160.129.06021 Boehringer Ingelheim Investigational Site
GLORIA-AF Registry Program - Second and Third Phases
China
Czech Republic
Ceske Budejovice : Nemocnice Ceske Budejovice
Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)
Olomouc : FN Olomouc
Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)
Prague : NA Homolce Hospital
ASA Plavix Feasibility Study With WATCHMAN Left Atrial Appendage Closure Technology
Prague : Institute for Clinical and Experimental Medicine (IKEM)
REVOLUTION (WFCC-133)
Denmark
Aarhus :
BIOTRONIK IMPACT Study
Aarhus : Skejby Hospital
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
France
Abbeville : CHG
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Abbeville : CH Général d'Abbeville
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Aix En Provence : CH du Pays d'Aix
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Annecy : CH de la région d'Annecy
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Antony : Hopital Privé
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
View More »
Argenteuil : CH d'Argentueil
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Arras : CH d'ARRAS
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Aurillac : CH d'AURILLAC
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Auxerre : CH
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Auxerre : CH d'AUXERRE
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Avignon : CH
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Avignon : CH d'AVIGNON
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Bordeaux : Hôpital Cardiologique du Haut-Lévêque Updated
ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial
Bordeaux : Clinique de Bordeaux Cauderan
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Bordeaux : University Hospital
Comparison of Externally Versus Internally Cooled Tip Catheter Ablation in Paroxysmal Atrial Fibrillation
Bordeaux : HHL Hop. Haut-Lévêque
REVOLUTION (WFCC-133)
Bordeaux : Hôpital Saint André -CHU de Bordeaux
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Bourges : Centre Hospitalier Jacques Coeur
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Brest : CHU de Brest
Prevention of Atrial Fibrillation by Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter
Bry Sur Marne : Hôpital Sainte Camille
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Caen : CHU
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Cannes : CH de Cannes
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Castres : CH
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Castres : CH de Castres
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Chalon Sur Saone : CH William Morey
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Chartres : Les Hôpitaux de Chartres
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Chateauroux : CH de CHATEAUROUX
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Cherbourg : CH Public du Cotentin
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Clamart : HIA Percy
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Clamart : HIA Percy
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Clermont Ferrand : Hôpital Gabriel Montpied
Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)
Clermont Ferrand : CHU de Clermont-Ferrand
Prevention of Atrial Fibrillation by Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter
Colmar : Hôpital Schweitzer
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Colmar : CHG Louis Pasteur
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Dinan : CH René Pleven
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Dinan : Ch Dinan
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Dole : CH
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Douarnenez : CH de DOUARNENEZ
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Dunkerque : CH
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Evreux : CH
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Evreux : CHI Eure-Seine
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Firminy : CH de Firminy
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Grenoble : CH
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Grenoble : CHU de Grenoble
Prevention of Atrial Fibrillation by Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter
Haguenau : CH d'HAGUENAU
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
La-roche-sur-yon : Centre Hospitalier Départemental Les Oudairies
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Laval : CH de LAVAL
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Le Chesnay : CMC Parly II
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Le Chesnay : Clinique Parly II - Centre Hospitalier de Versailles
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Le Havre : CH
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Le Mans : CH du Mans
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Lille : CHRU de Lille
Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)
Lille : CHU Lille
European Carto XP Registry for Validating Specialized CFAE Software
Limoges : CH
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Lomme : CH Saint Philibert
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Lorient : CH Bretagne Sud
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Marseille : Hôpital La Timone
Ability of Home Monitoring® to Detect and Manage the Inappropriate Diagnoses in Implantable Cardioverter Defibrillators.
Marseille : CHU La Timone
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Marseille : Clinique de la Casamance
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Marseille : Clinique Bouchard
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Marseille : Hopital Saint Joseph
European Carto XP Registry for Validating Specialized CFAE Software
Marseille : Hôpital de la Timone
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Martigues : CH
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Metz : CH
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Metz : CHR Notre Dame de bon secours
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Montauban : CH de MONTAUBAN
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Montbeliard : CH de MONTBELIARD
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Montfermeil : Intercommunal General Hospital LE RAINCY- MONTFERMEIL
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Montpellier : CHU
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Montpellier : CHRU Hôpital de Villeneuve
Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)
Montpellier : CHU Arnaud de Villeneuve
European Carto XP Registry for Validating Specialized CFAE Software
Montpellier : CHU de Montpellier
Prevention of Atrial Fibrillation by Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter
Mulhouse : CH
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Nancy : CHU Hôpital de Brabois
European Carto XP Registry for Validating Specialized CFAE Software
Nancy : HDB CHU de Nancy
REVOLUTION (WFCC-133)
Nantes : CHU Nantes
European Carto XP Registry for Validating Specialized CFAE Software
Narbonne : CH de Narbonne
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Neuilly : Ambroise Paré
European Carto XP Registry for Validating Specialized CFAE Software
Neuilly sur Seine : Clinique Ambroise Paré
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Nice : Hôpital Pasteur
Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)
Nimes : Hopital Les Franciscaines
European Carto XP Registry for Validating Specialized CFAE Software
Orléans : CHR d'ORLEANS
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Paris : Hôpital La Pitié-Salpetrière
Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)
Pessac : Hopital Cardiologique du Haut Leveque
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Pessac : CHU Haut Lévêque
Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)
Quincy-sous-Sénart : Hopital Privé Claude Galien
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Rennes : Polyclinique Saint Laurent
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Rennes : CHU
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Rennes : CHU des Rennes, Hôpital de Pontchaillou
Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)
Rennes : CHU de Rennes
Prevention of Atrial Fibrillation by Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter
Roubaix : CH de Roubaix
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Rouen : CHU
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Rouen : CHU de Rouen
Prevention of Atrial Fibrillation by Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter
Saint Etienne : CHU
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Saint Etienne : Hôpital Nord
Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)
Saint Jean de Verges : CHI du Val d'Ariège
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Saint Laurent du Var : Institut Arnalt Tzanck
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Saint-brieuc : CH de SAINT BRIEUC
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Saintes : CH de Saintonge
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Saint-etienne : CHU de Saint-Etienne
Prevention of Atrial Fibrillation by Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter
Saint-malo : CH de SAINT-MALO
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Schiltigheim : CMCO
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Thionville : CH
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Toulon : CH Toulon
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Toulon : CH de TOULON
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Toulouse : Centre Hospitalier de Rangueil
Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)
Toulouse : Clinique Pasteur
Comparison of Externally Versus Internally Cooled Tip Catheter Ablation in Paroxysmal Atrial Fibrillation
Troyes : CH de TROYES
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Valenciennes : CH
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
Valenciennes : CH de Valenciennes
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Vannes : CH Bretagne Atlantique
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Villeneuve Saint Georges : CHI de Villeneuve
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
Germany
Bad Berka : Zentralklinik Bad Berka
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
Bad Krozingen : Herz-Zentrum
A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy
Bad Krozingen : Herz-Zentrum Bad Krozingen Updated
ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial
Bad Krozingen : Herz-Zentrum Bad Krozingen
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Bad Krozingen : Herzzentrum Bad Krozingen, Elektrophysiologie
Ventricular Pacing Site Selection (V-PASS)
View More »
Bad Nauheim : Kerckhoff Klinik
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Bad Oeynhausen : Herz-und Diabeteszentrum NRW
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Bad Oeynhausen : Herz- und Diabeteszentrum Nordrhein-Westfalen
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
Berlin : Charité Campus Mitte
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
Berlin : Vivantes-Klinikum am Urban
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
Berlin : Charité Campus Virchow-Klinikum
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
Berlin : Franz-Volhard-Klinik, Universitätsklinikum Charité
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
Berlin : Charitè Berlin
Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)
Bielefeld : Städtische Kliniken Bielefeld
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
Bochum : Knappschaftskrankenhaus Bochum
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Bonn : Saint Marien Hospital Bonn
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Bonn : St. Marien Hospital
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
Bremen : Zentralkrankenhaus Links der Weser, Siebels & Langes Partnerschaft
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
Coburg : Klinikum Coburg
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Coburg : Klinikum Coburg
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
Coburg : Klinikum Coburg
Mode Evaluation in Sick Sinus Syndrome Trial (MODEST)
Coburg : Klinikum Coburg GmbH
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Dortmund : Klinikum Dortmund
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Dresden : Praxisklinik Herz and Gefaesse
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Dresden : Städtisches Klinikum Dresden-Friedrichstadt
Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)
Düsseldorf : Evangelisches Krankenhaus Düsseldorf
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
Essen : Universitätsklinikum Essen
DISCOVERY: Diagnostic Data and Genetic Polymorphisms in ICD Patients.
Essen : Universitätsklinikum Essen
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Frankfurt : Sankt Katharinen Hospital / Cardiovasculares Centrum
ASA Plavix Feasibility Study With WATCHMAN Left Atrial Appendage Closure Technology
Frankfurt : CCB - Cardioaniologisches Centrum Bethanien
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Frankfurt : Cardioangiologisches Centrum Bethanien - CCB
FIRE AND ICE: Comparative Study of Two Ablation Procedures in Patients With Atrial Fibrilation
Goettingen : Universitätsmedizin Göttingen (UMG), Kardiologie und Pneumologie
Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion
Gottingen : Universitatsmedizin Gottingen Abteilung Kardiologie und
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Göttingen : Universitätsklinikum Göttingen
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
Greifswald : Universitätsklinikum der Ernst-Moritz-Arndt-Universität Greifswald
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
Hamburg : University Heart Center Updated
ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial
Hamburg : ASKLEPIOS KLINIK St. Georg
Alster Man and Machine: Comparison of Manual and Mechanical Remote Robotic Catheter Ablation for Drug-Refractory Atrial Fibrillation
Hamburg : Asklepios Klinik St. Georg
Alster-Lost-AF-Study
Hamburg : Asklepios Klinik St. Georg
Atrial Fibrillation Management in Congestive Heart Failure With Ablation
Hamburg : University Hospital Eppendorf
CatHeter Ablation of perSistEnd Atrial Fibrillation: Pulmonary Vein Isolation Versus Defragmentation. The CHASE-AF Study
Hamburg : Asklepios Klinik Barmbek
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Hamburg : Universitares Herrzentrum Hamburg
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Hamburg : Asklepios Klinik Saint George
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Hamburg : Asklepios Klinik St. Georg
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Hamburg : Klinik St. Georg
European Carto XP Registry for Validating Specialized CFAE Software
Hamburg : Universitätskrankenhaus Eppendorf
Mode Evaluation in Sick Sinus Syndrome Trial (MODEST)
Hamburg : General Hospital St. Georg, Department of Cardiology
Randomized Trial of Two Different Strategies to Treat Paroxysmal Atrial Fibrillation
Hamburg : University Cardiac Center
Randomized Trial of Two Different Strategies to Treat Paroxysmal Atrial Fibrillation
Hamburg : University Cardiac Center
Recurrence of Atrial Fibrillation in Patients With Dual-Chamber Pacemakers and Drug Therapy
Heidelberg : Department of Cardiology, University of Heidelberg
Real-Time Assessment of Cryoballoon Pulmonary Vein Isolation Using a Novel Circular Mapping Catheter
Karlsruhe : Saint Vincentius-Kliniken
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Karlsruhe : Stadtisches Klinikum Karlsruhe
European Carto XP Registry for Validating Specialized CFAE Software
Konstanz : Herzzentrum Konstanz
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
Konstanz : Herz-Zentrum-Bodensee Konstanz
FIRE AND ICE: Comparative Study of Two Ablation Procedures in Patients With Atrial Fibrilation
Landshut : Krankenhaus Landshut-Achdorf
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
Leipzig : Herzzentrum Leipzig
ASA Plavix Feasibility Study With WATCHMAN Left Atrial Appendage Closure Technology
Leipzig : Herzzentrum Leipzig
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Magdeburg : University Hospital Magdeburg; Div. of Cardiology
Irbesartan and Adhesion Molecules in AF
Mannheim : University Hospital of Mannheim
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Muenster : University Hospital of Muenster
Flecainide-Short Long Study (Flec-SL)
Munich : Deutsches Herzzentrum Muenchen Updated
ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial
Munich : Isar Zentrum
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
Münster : University Hospital, Department of Cardiology
Randomized Trial of Two Different Strategies to Treat Paroxysmal Atrial Fibrillation
Paderborn : St. Vincenz-Krankenhaus
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
Papenburg : Kardiologische Gemeinschaftspraxis
Mode Evaluation in Sick Sinus Syndrome Trial (MODEST)
Rastatt : Kreiskrankenhaus Rastatt
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Regensburg : Chefarzt der Medizinischen Klinik III/Kardiologie
ASA Plavix Feasibility Study With WATCHMAN Left Atrial Appendage Closure Technology
Rostock : Universitat Rostock
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Rostock : Universitätsklinikum Rostock
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
Starnberg-Percha : Kardiologische Praxis
Mode Evaluation in Sick Sinus Syndrome Trial (MODEST)
Tubingen :
BIOTRONIK IMPACT Study
Ulm : University Hospital
Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)
Villingen :
BIOTRONIK IMPACT Study
Weimar : Sophien- und Hufelandklinikum GmbH
Mode Evaluation in Sick Sinus Syndrome Trial (MODEST)
Greece
Athens : Ygeia Hospital
Current Clinical Practice in the Management of Atrial Fibrillation in Greece: the MANAGE-AF Study
Athens : KAT General Hospital
Current Clinical Practice in the Management of Atrial Fibrillation in Greece: the MANAGE-AF Study
Athens : Laiko General Hospital
Current Clinical Practice in the Management of Atrial Fibrillation in Greece: the MANAGE-AF Study
Athens : General Hospital of Athens Evangelismos
Current Clinical Practice in the Management of Atrial Fibrillation in Greece: the MANAGE-AF Study
Athens : 7th IKA Hospital of Athens
Current Clinical Practice in the Management of Atrial Fibrillation in Greece: the MANAGE-AF Study
View More »
Athens : Henry Dunant General Hospital
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Chalkida : General Hospital of Chalkida
Current Clinical Practice in the Management of Atrial Fibrillation in Greece: the MANAGE-AF Study
Chios : General Hospital of Chios
Current Clinical Practice in the Management of Atrial Fibrillation in Greece: the MANAGE-AF Study
Elefsina : Thriassio General Hospital of Elefsina
Current Clinical Practice in the Management of Atrial Fibrillation in Greece: the MANAGE-AF Study
Kavala : General Hospital of Kavala
Current Clinical Practice in the Management of Atrial Fibrillation in Greece: the MANAGE-AF Study
Komotini : General Hospital of Komotini Sismanoglio
Current Clinical Practice in the Management of Atrial Fibrillation in Greece: the MANAGE-AF Study
Ptolemaida : General Hospital of Ptolemaida Mpodosakeio
Current Clinical Practice in the Management of Atrial Fibrillation in Greece: the MANAGE-AF Study
Thessaloniki : Ippokrateio Hospital of Thessaloniki
Current Clinical Practice in the Management of Atrial Fibrillation in Greece: the MANAGE-AF Study
Thessaloniki : Agios Loukas Clinic
Current Clinical Practice in the Management of Atrial Fibrillation in Greece: the MANAGE-AF Study
Thessaloniki : 2nd IKA Hospital of Thessaloniki
Current Clinical Practice in the Management of Atrial Fibrillation in Greece: the MANAGE-AF Study
Hong Kong
Hong Kong : Merck Sharp & Dohme (Asia) Ltd.
A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM2)
Hungary
Budapest : Semmelweis Medical University
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
Debrecen : The Debrecen University of Medicine
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
Italy
Acquaviva delle Fonti : OFM Ospedale Generale Regionale
REVOLUTION (WFCC-133)
Asti : Ospedale Cardinal Massaia
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
Grosseto : Ospedale Misericordia di Grosseto
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Imperia : Ospedale di Imperia
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Milan : Policlinico San Donato
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
View More »
Milan : Merck Sharp & Dohme (Italia) S.P.A.
International Registry on Cardioversion of Atrial Fibrillation (MK-6621-051)
Milan : CCM Centro Cardiologico Monzino
REVOLUTION (WFCC-133)
Pavia : FONDAZIONE IRCCS, Dip. Cardiotoracovascolare (U.C.C.)
Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion
Rome : Policlinico Casilino
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
Rome : Policlinico Universitario Agostino Gemelli
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Seriate : Ospedale Bolognini
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Sesto San Giovanni : IRCCS, Multimedica
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
Japan
Abashiri : Boehringer Ingelheim Investigational Site 30
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Adachi-Ku : Boehringer Ingelheim Investigational Site 259
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Adachi-Ku : Boehringer Ingelheim Investigational Site 260
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Aira : Boehringer Ingelheim Investigational Site 847
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Aizu-Wakamatsu : Boehringer Ingelheim Investigational Site 91
Post-Marketing Surveillance of Prazaxa on the Long-term Use
View More »
Akashi : Boehringer Ingelheim Investigational Site 637
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Akita : Boehringer Ingelheim Investigational Site 70
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Akita : Boehringer Ingelheim Investigational Site 71
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Akita : Boehringer Ingelheim Investigational Site 72
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ako : Boehringer Ingelheim Investigational Site 621
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Akune : Boehringer Ingelheim Investigational Site 846
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Amagasaki : Boehringer Ingelheim Investigational Site 623
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Amagasaki : Boehringer Ingelheim Investigational Site 624
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Amagasaki : Boehringer Ingelheim Investigational Site 625
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Amagasaki : Boehringer Ingelheim Investigational Site 626
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Amakusa : Boehringer Ingelheim Investigational Site 824
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Anan : Boehringer Ingelheim Investigational Site 717
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Anjo : Boehringer Ingelheim Investigational Site 450
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Annaka : Boehringer Ingelheim Investigational Site 141
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Anzai : Boehringer Ingelheim Investigational Site 449
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Aomori : Boehringer Ingelheim Investigational Site 40
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Aomori : Boehringer Ingelheim Investigational Site 38
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Aomori : Boehringer Ingelheim Investigational Site 39
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Arakawa-Ku : Boehringer Ingelheim Investigational Site 234
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Arita : Boehringer Ingelheim Investigational Site 649
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Asahi : Boehringer Ingelheim Investigational Site 191
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Asahikawa : Boehringer Ingelheim Investigational Site 1
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Asahikawa : Boehringer Ingelheim Investigational Site 3
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Asahikawa : Boehringer Ingelheim Investigational Site 2
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Asakura : Boehringer Ingelheim Investigational Site 772
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ashikaga : Boehringer Ingelheim Investigational Site 136
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Asigarakami : Boehringer Ingelheim Investigational Site 340
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Atami : Boehringer Ingelheim Investigational Site 437
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Azumino : Boehringer Ingelheim Investigational Site 394
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Beppu : Boehringer Ingelheim Investigational Site 835
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Bunkyo-Ku : Boehringer Ingelheim Investigational Site 291
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Bunkyo-Ku : Boehringer Ingelheim Investigational Site 290
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Bunkyo-Ku : Boehringer Ingelheim Investigational Site 287
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Bunkyo-Ku : Boehringer Ingelheim Investigational Site 288
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Bunkyo-Ku : Boehringer Ingelheim Investigational Site 289
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Buzen : Boehringer Ingelheim Investigational Site 785
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Chiba : Boehringer Ingelheim Investigational Site 206
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Chiba : Boehringer Ingelheim Investigational Site 207
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Chiba : Boehringer Ingelheim Investigational Site 208
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Chigasaki : Boehringer Ingelheim Investigational Site 325
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Chikuma : Boehringer Ingelheim Investigational Site 407
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Chikusei : Boehringer Ingelheim Investigational Site 119
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Chikushino : Boehringer Ingelheim Investigational Site 771
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Chiyoda-ku : Boehringer Ingelheim Investigational Site 258
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Chiyoda-ku : Boehringer Ingelheim Investigational Site 257
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Chofu : Boehringer Ingelheim Investigational Site 270
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Choshi : Boehringer Ingelheim Investigational Site 210
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Chuo-ku : Boehringer Ingelheim Investigational Site 266
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Daito : Boehringer Ingelheim Investigational Site 582
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Date : Boehringer Ingelheim Investigational Site 4
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Date : Boehringer Ingelheim Investigational Site 90
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ebetsu : Boehringer Ingelheim Investigational Site 9
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ebina : Boehringer Ingelheim Investigational Site 324
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ebina : Boehringer Ingelheim Investigational Site 323
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ebino : Boehringer Ingelheim Investigational Site 836
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ebino : Boehringer Ingelheim Investigational Site 837
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Echizen : Boehringer Ingelheim Investigational Site 382
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Edogawa-Ku : Boehringer Ingelheim Investigational Site 224
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Edogawa-Ku : Boehringer Ingelheim Investigational Site 225
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Edogawa-Ku : Boehringer Ingelheim Investigational Site 226
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Eniwa : Boehringer Ingelheim Investigational Site 8
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Fuchu : Boehringer Ingelheim Investigational Site 283
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Fuchu : Boehringer Ingelheim Investigational Site 284
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Fuchu : Boehringer Ingelheim Investigational Site 285
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Fuefuki : Boehringer Ingelheim Investigational Site 393
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Fuji : Boehringer Ingelheim Investigational Site 448
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Fujieda : Boehringer Ingelheim Investigational Site 436
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Fujimi : Boehringer Ingelheim Investigational Site 188
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Fujisawa : Boehringer Ingelheim Investigational Site 342
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Fujisawa : Boehringer Ingelheim Investigational Site 343
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Fukuchiyama : Boehringer Ingelheim Investigational Site 524
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Fukuchiyama : Boehringer Ingelheim Investigational Site 525
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Fukui : Boehringer Ingelheim Investigational Site 385
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Fukui : Boehringer Ingelheim Investigational Site 386
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Fukui : Boehringer Ingelheim Investigational Site 384
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Fukuoka : Boehringer Ingelheim Investigational Site 777
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Fukuoka : Boehringer Ingelheim Investigational Site 779
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Fukuoka : Boehringer Ingelheim Investigational Site 781
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Fukuoka : Boehringer Ingelheim Investigational Site 782
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Fukuoka : Boehringer Ingelheim Investigational Site 783
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Fukuoka : Boehringer Ingelheim Investigational Site 784
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Fukuoka : Boehringer Ingelheim Investigational Site 775
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Fukuoka : Boehringer Ingelheim Investigational Site 776
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Fukuoka : Boehringer Ingelheim Investigational Site 778
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Fukuoka : Boehringer Ingelheim Investigational Site 780
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Fukushima : Boehringer Ingelheim Investigational Site 99
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Fukushima : Boehringer Ingelheim Investigational Site 101
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Fukushima : Boehringer Ingelheim Investigational Site 100
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Fukushima : Boehringer Ingelheim Investigational Site 102
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Fukuyama : Boehringer Ingelheim Investigational Site 699
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Fukuyama : Boehringer Ingelheim Investigational Site 696
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Fukuyama : Boehringer Ingelheim Investigational Site 697
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Fukuyama : Boehringer Ingelheim Investigational Site 698
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Futtsu : Boehringer Ingelheim Investigational Site 215
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Gamagori : Boehringer Ingelheim Investigational Site 454
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Gifu : Boehringer Ingelheim Investigational Site 413
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Gifu : Boehringer Ingelheim Investigational Site 415
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Gifu : Boehringer Ingelheim Investigational Site 416
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Gifu : Boehringer Ingelheim Investigational Site 414
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Goshogawara : Boehringer Ingelheim Investigational Site 33
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Goto : Boehringer Ingelheim Investigational Site 801
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Gotsu : Boehringer Ingelheim Investigational Site 658
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Gyoda : Boehringer Ingelheim Investigational Site 172
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Habikino : Boehringer Ingelheim Investigational Site 528
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Habikino : Boehringer Ingelheim Investigational Site 529
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hachinohe : Boehringer Ingelheim Investigational Site 41
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hachinohe : Boehringer Ingelheim Investigational Site 42
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hachioji : Boehringer Ingelheim Investigational Site 272
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hachioji : Boehringer Ingelheim Investigational Site 275
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hachioji : Boehringer Ingelheim Investigational Site 276
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hachioji : Boehringer Ingelheim Investigational Site 273
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hachioji : Boehringer Ingelheim Investigational Site 274
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hachioji : Boehringer Ingelheim Investigational Site 277
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hadano-Shi : Boehringer Ingelheim Investigational Site 327
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hagi : Boehringer Ingelheim Investigational Site 713
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hakodate : Boehringer Ingelheim Investigational Site 26
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hakodate : Boehringer Ingelheim Investigational Site 25
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hakodate : Boehringer Ingelheim Investigational Site 27
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hakui : Boehringer Ingelheim Investigational Site 373
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hakusan : Boehringer Ingelheim Investigational Site 381
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hamada : Boehringer Ingelheim Investigational Site 665
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hamada : Boehringer Ingelheim Investigational Site 666
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hamamatsu : Boehringer Ingelheim Investigational Site 445
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hamamatsu : Boehringer Ingelheim Investigational Site 446
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hamamatsu : Boehringer Ingelheim Investigational Site 447
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hamamatsu : Boehringer Ingelheim Investigational Site 439
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hamamatsu : Boehringer Ingelheim Investigational Site 440
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hamamatsu : Boehringer Ingelheim Investigational Site 441
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hamamatsu : Boehringer Ingelheim Investigational Site 442
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hamamatsu : Boehringer Ingelheim Investigational Site 443
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hamamatsu : Boehringer Ingelheim Investigational Site 444
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Handa : Boehringer Ingelheim Investigational Site 464
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Handa : Boehringer Ingelheim Investigational Site 465
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hashimoto : Boehringer Ingelheim Investigational Site 645
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hashimoto : Boehringer Ingelheim Investigational Site 646
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hata : Boehringer Ingelheim Investigational Site 756
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hidaka : Boehringer Ingelheim Investigational Site 185
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Higashi-Hiroshima : Boehringer Ingelheim Investigational Site 693
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Higashiibaragi : Boehringer Ingelheim Investigational Site 122
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Higashiibaragi : Boehringer Ingelheim Investigational Site 121
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Higashikagawa : Boehringer Ingelheim Investigational Site 735
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Higashimatsusima : Boehringer Ingelheim Investigational Site 65
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Higashimatsusima : Boehringer Ingelheim Investigational Site 66
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Higashimatsusima : Boehringer Ingelheim Investigational Site 64
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Higashimatsuyama : Boehringer Ingelheim Investigational Site 184
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Higashine : Boehringer Ingelheim Investigational Site 85
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Higashine : Boehringer Ingelheim Investigational Site 84
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Higashi-Osaka : Boehringer Ingelheim Investigational Site 584
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Higashi-Osaka : Boehringer Ingelheim Investigational Site 585
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Higashitamaoki : Boehringer Ingelheim Investigational Site 86
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Higashi-Usuki : Boehringer Ingelheim Investigational Site 843
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hikari : Boehringer Ingelheim Investigational Site 707
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hiki : Boehringer Ingelheim Investigational Site 187
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hikone : Boehringer Ingelheim Investigational Site 499
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hikone : Boehringer Ingelheim Investigational Site 500
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Himeji : Boehringer Ingelheim Investigational Site 627
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Himeji : Boehringer Ingelheim Investigational Site 628
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Himeji : Boehringer Ingelheim Investigational Site 631
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Himeji : Boehringer Ingelheim Investigational Site 632
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Himeji : Boehringer Ingelheim Investigational Site 633
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Himeji : Boehringer Ingelheim Investigational Site 634
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Himeji : Boehringer Ingelheim Investigational Site 630
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Himeji : Boehringer Ingelheim Investigational Site 629
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Himi : Boehringer Ingelheim Investigational Site 369
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hirakata : Boehringer Ingelheim Investigational Site 592
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hirakata : Boehringer Ingelheim Investigational Site 593
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hirakata : Boehringer Ingelheim Investigational Site 594
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hirakata : Boehringer Ingelheim Investigational Site 595
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hiratsuka : Boehringer Ingelheim Investigational Site 344
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hirosaki : Boehringer Ingelheim Investigational Site 36
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hirosaki : Boehringer Ingelheim Investigational Site 34
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hirosaki : Boehringer Ingelheim Investigational Site 35
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hiroshima : Boehringer Ingelheim Investigational Site 681
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hiroshima : Boehringer Ingelheim Investigational Site 682
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hiroshima : Boehringer Ingelheim Investigational Site 683
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hiroshima : Boehringer Ingelheim Investigational Site 684
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hiroshima : Boehringer Ingelheim Investigational Site 685
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hiroshima : Boehringer Ingelheim Investigational Site 686
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hiroshima : Boehringer Ingelheim Investigational Site 687
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hiroshima : Boehringer Ingelheim Investigational Site 688
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hiroshima : Boehringer Ingelheim Investigational Site 680
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hita : Boehringer Ingelheim Investigational Site 834
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hitachinaka : Boehringer Ingelheim Investigational Site 105
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hitachinaka : Boehringer Ingelheim Investigational Site 106
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hitachiota : Boehringer Ingelheim Investigational Site 112
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hofu : Boehringer Ingelheim Investigational Site 715
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hunagashi : Boehringer Ingelheim Investigational Site 209
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Huwa : Boehringer Ingelheim Investigational Site 422
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Hyuga : Boehringer Ingelheim Investigational Site 844
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ibaraki : Boehringer Ingelheim Investigational Site 527
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ibi : Boehringer Ingelheim Investigational Site 423
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ibusuki : Boehringer Ingelheim Investigational Site 848
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ibusuki : Boehringer Ingelheim Investigational Site 849
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ichihara : Boehringer Ingelheim Investigational Site 199
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ichihara : Boehringer Ingelheim Investigational Site 200
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ichihara : Boehringer Ingelheim Investigational Site 201
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ichikikushikino : Boehringer Ingelheim Investigational Site 845
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ichinomiya : Boehringer Ingelheim Investigational Site 451
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Iida : Boehringer Ingelheim Investigational Site 410
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Iizuka : Boehringer Ingelheim Investigational Site 774
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ikeda : Boehringer Ingelheim Investigational Site 583
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ikoma : Boehringer Ingelheim Investigational Site 640
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ina : Boehringer Ingelheim Investigational Site 395
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Inazawa : Boehringer Ingelheim Investigational Site 452
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Inuyama : Boehringer Ingelheim Investigational Site 457
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Inzai : Boehringer Ingelheim Investigational Site 192
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Inzai : Boehringer Ingelheim Investigational Site 193
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Iruma : Boehringer Ingelheim Investigational Site 186
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Isahaya : Boehringer Ingelheim Investigational Site 811
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ise : Boehringer Ingelheim Investigational Site 486
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Isehara : Boehringer Ingelheim Investigational Site 305
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Isesaki : Boehringer Ingelheim Investigational Site 142
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ishioka : Boehringer Ingelheim Investigational Site 118
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Itabashi-Ku : Boehringer Ingelheim Investigational Site 280
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Itabashi-Ku : Boehringer Ingelheim Investigational Site 278
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Itabashi-Ku : Boehringer Ingelheim Investigational Site 279
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Itabashi-Ku : Boehringer Ingelheim Investigational Site 281
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Itami : Boehringer Ingelheim Investigational Site 599
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Itano : Boehringer Ingelheim Investigational Site 723
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Itoigawa : Boehringer Ingelheim Investigational Site 348
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Itoshima : Boehringer Ingelheim Investigational Site 764
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Iwaki : Boehringer Ingelheim Investigational Site 88
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Iwaki : Boehringer Ingelheim Investigational Site 89
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Iwakuni : Boehringer Ingelheim Investigational Site 705
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Iwakuni : Boehringer Ingelheim Investigational Site 706
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Iwakura : Boehringer Ingelheim Investigational Site 456
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Iwanuma : Boehringer Ingelheim Investigational Site 52
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Iwata : Boehringer Ingelheim Investigational Site 438
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Izu : Boehringer Ingelheim Investigational Site 424
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Izumi : Boehringer Ingelheim Investigational Site 597
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Izumisano : Boehringer Ingelheim Investigational Site 552
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Izumisano : Boehringer Ingelheim Investigational Site 551
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Izumo : Boehringer Ingelheim Investigational Site 660
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Izumo : Boehringer Ingelheim Investigational Site 659
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Izumo : Boehringer Ingelheim Investigational Site 661
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Joetsu : Boehringer Ingelheim Investigational Site 351
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Joetsu : Boehringer Ingelheim Investigational Site 352
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kadoma : Boehringer Ingelheim Investigational Site 596
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kagoshima : Boehringer Ingelheim Investigational Site 850
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kagoshima : Boehringer Ingelheim Investigational Site 851
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kagoshima : Boehringer Ingelheim Investigational Site 852
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kaizuka : Boehringer Ingelheim Investigational Site 530
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kaizuka : Boehringer Ingelheim Investigational Site 531
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kakamigahara : Boehringer Ingelheim Investigational Site 412
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kakogawa : Boehringer Ingelheim Investigational Site 600
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kakogawa : Boehringer Ingelheim Investigational Site 601
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kakogawa : Boehringer Ingelheim Investigational Site 602
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kamiamakusa : Boehringer Ingelheim Investigational Site 822
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kamiina : Boehringer Ingelheim Investigational Site 401
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kamiminochi : Boehringer Ingelheim Investigational Site 402
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kamisu : Boehringer Ingelheim Investigational Site 113
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kamisu : Boehringer Ingelheim Investigational Site 114
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kamo : Boehringer Ingelheim Investigational Site 411
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kamo : Boehringer Ingelheim Investigational Site 425
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kamo : Boehringer Ingelheim Investigational Site 346
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kanazawa : Boehringer Ingelheim Investigational Site 375
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kanazawa : Boehringer Ingelheim Investigational Site 376
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kanazawa : Boehringer Ingelheim Investigational Site 377
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kanazawa : Boehringer Ingelheim Investigational Site 378
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kanuma : Boehringer Ingelheim Investigational Site 131
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kanuma : Boehringer Ingelheim Investigational Site 132
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kariya : Boehringer Ingelheim Investigational Site 455
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kasaoka : Boehringer Ingelheim Investigational Site 672
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kashihara : Boehringer Ingelheim Investigational Site 639
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kashiwa : Boehringer Ingelheim Investigational Site 212
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kashiwa : Boehringer Ingelheim Investigational Site 211
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kasuga : Boehringer Ingelheim Investigational Site 766
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kasugai : Boehringer Ingelheim Investigational Site 459
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kasugai : Boehringer Ingelheim Investigational Site 460
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kasuya : Boehringer Ingelheim Investigational Site 768
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Katsushika-Ku : Boehringer Ingelheim Investigational Site 221
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Katsushika-Ku : Boehringer Ingelheim Investigational Site 223
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Katsushika-Ku : Boehringer Ingelheim Investigational Site 219
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Katsushika-Ku : Boehringer Ingelheim Investigational Site 220
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Katsushika-Ku : Boehringer Ingelheim Investigational Site 222
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Katta : Boehringer Ingelheim Investigational Site 51
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kawagoe : Boehringer Ingelheim Investigational Site 176
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kawaguchi : Boehringer Ingelheim Investigational Site 177
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kawaguchi : Boehringer Ingelheim Investigational Site 179
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kawaguchi : Boehringer Ingelheim Investigational Site 178
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kawakita : Boehringer Ingelheim Investigational Site 374
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kawanishi : Boehringer Ingelheim Investigational Site 622
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kawasaki : Boehringer Ingelheim Investigational Site 329
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kawasaki : Boehringer Ingelheim Investigational Site 330
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kawasaki : Boehringer Ingelheim Investigational Site 332
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kawasaki : Boehringer Ingelheim Investigational Site 333
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kawasaki : Boehringer Ingelheim Investigational Site 334
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kawasaki : Boehringer Ingelheim Investigational Site 328
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kawasaki : Boehringer Ingelheim Investigational Site 331
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kawasaki : Boehringer Ingelheim Investigational Site 335
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kidukawa : Boehringer Ingelheim Investigational Site 526
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kikuchi : Boehringer Ingelheim Investigational Site 812
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kimitsu : Boehringer Ingelheim Investigational Site 196
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kirishima : Boehringer Ingelheim Investigational Site 854
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kishiwada : Boehringer Ingelheim Investigational Site 532
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kita-akita : Boehringer Ingelheim Investigational Site 78
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kitagunma : Boehringer Ingelheim Investigational Site 154
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kitakami : Boehringer Ingelheim Investigational Site 50
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kitakata : Boehringer Ingelheim Investigational Site 92
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kita-ku : Boehringer Ingelheim Investigational Site 294
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kitakyushu : Boehringer Ingelheim Investigational Site 786
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kitakyushu : Boehringer Ingelheim Investigational Site 787
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kitakyushu : Boehringer Ingelheim Investigational Site 788
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kitakyushu : Boehringer Ingelheim Investigational Site 793
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kitakyushu : Boehringer Ingelheim Investigational Site 789
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kitakyushu : Boehringer Ingelheim Investigational Site 790
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kitakyushu : Boehringer Ingelheim Investigational Site 791
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kitakyushu : Boehringer Ingelheim Investigational Site 792
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kitakyushu : Boehringer Ingelheim Investigational Site 794
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kitami : Boehringer Ingelheim Investigational Site 29
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kitami : Boehringer Ingelheim Investigational Site 28
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kitamoto : Boehringer Ingelheim Investigational Site 189
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kitamoto : Boehringer Ingelheim Investigational Site 190
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kitanagoya : Boehringer Ingelheim Investigational Site 470
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kobe : Boehringer Ingelheim Investigational Site 605
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kobe : Boehringer Ingelheim Investigational Site 606
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kobe : Boehringer Ingelheim Investigational Site 608
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kobe : Boehringer Ingelheim Investigational Site 609
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kobe : Boehringer Ingelheim Investigational Site 611
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kobe : Boehringer Ingelheim Investigational Site 612
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kobe : Boehringer Ingelheim Investigational Site 613
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kobe : Boehringer Ingelheim Investigational Site 614
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kobe : Boehringer Ingelheim Investigational Site 615
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kobe : Boehringer Ingelheim Investigational Site 616
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kobe : Boehringer Ingelheim Investigational Site 607
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kobe : Boehringer Ingelheim Investigational Site 610
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kochi : Boehringer Ingelheim Investigational Site 749
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kochi : Boehringer Ingelheim Investigational Site 750
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kochi : Boehringer Ingelheim Investigational Site 752
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kochi : Boehringer Ingelheim Investigational Site 751
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kochi : Boehringer Ingelheim Investigational Site 748
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kodaira : Boehringer Ingelheim Investigational Site 240
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kodaira : Boehringer Ingelheim Investigational Site 241
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kofu : Boehringer Ingelheim Investigational Site 387
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kofu : Boehringer Ingelheim Investigational Site 388
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kofu : Boehringer Ingelheim Investigational Site 389
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Koga : Boehringer Ingelheim Investigational Site 763
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Koganei : Boehringer Ingelheim Investigational Site 239
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kokubu : Boehringer Ingelheim Investigational Site 235
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Komatsu : Boehringer Ingelheim Investigational Site 380
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Komatsujima : Boehringer Ingelheim Investigational Site 718
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Konan : Boehringer Ingelheim Investigational Site 458
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Koriyama : Boehringer Ingelheim Investigational Site 94
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Koriyama : Boehringer Ingelheim Investigational Site 93
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Koshigaya : Boehringer Ingelheim Investigational Site 166
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Koshigaya : Boehringer Ingelheim Investigational Site 165
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Koto-ku : Boehringer Ingelheim Investigational Site 227
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Koto-ku : Boehringer Ingelheim Investigational Site 228
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Koto-ku : Boehringer Ingelheim Investigational Site 229
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Koyama : Boehringer Ingelheim Investigational Site 133
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kuki : Boehringer Ingelheim Investigational Site 167
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kuki : Boehringer Ingelheim Investigational Site 168
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kumagaya : Boehringer Ingelheim Investigational Site 171
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kumagaya : Boehringer Ingelheim Investigational Site 170
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kumagaya : Boehringer Ingelheim Investigational Site 175
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kumamoto : Boehringer Ingelheim Investigational Site 816
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kumamoto : Boehringer Ingelheim Investigational Site 817
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kumamoto : Boehringer Ingelheim Investigational Site 819
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kumamoto : Boehringer Ingelheim Investigational Site 814
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kumamoto : Boehringer Ingelheim Investigational Site 815
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kumamoto : Boehringer Ingelheim Investigational Site 818
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kumamoto : Boehringer Ingelheim Investigational Site 820
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kurashiki : Boehringer Ingelheim Investigational Site 674
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kurashiki : Boehringer Ingelheim Investigational Site 675
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kurashiki : Boehringer Ingelheim Investigational Site 676
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kure : Boehringer Ingelheim Investigational Site 678
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kure : Boehringer Ingelheim Investigational Site 679
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kurihara : Boehringer Ingelheim Investigational Site 53
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kurume : Boehringer Ingelheim Investigational Site 760
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kurume : Boehringer Ingelheim Investigational Site 761
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kurume : Boehringer Ingelheim Investigational Site 762
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kurume : Boehringer Ingelheim Investigational Site 759
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kusatsu : Boehringer Ingelheim Investigational Site 496
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kushiro : Boehringer Ingelheim Investigational Site 6
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kushiro : Boehringer Ingelheim Investigational Site 7
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kushiro : Boehringer Ingelheim Investigational Site 5
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kyotabe : Boehringer Ingelheim Investigational Site 503
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kyoto : Boehringer Ingelheim Investigational Site 504
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kyoto : Boehringer Ingelheim Investigational Site 508
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kyoto : Boehringer Ingelheim Investigational Site 509
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kyoto : Boehringer Ingelheim Investigational Site 510
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kyoto : Boehringer Ingelheim Investigational Site 512
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kyoto : Boehringer Ingelheim Investigational Site 513
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kyoto : Boehringer Ingelheim Investigational Site 514
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kyoto : Boehringer Ingelheim Investigational Site 518
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kyoto : Boehringer Ingelheim Investigational Site 519
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kyoto : Boehringer Ingelheim Investigational Site 520
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kyoto : Boehringer Ingelheim Investigational Site 505
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kyoto : Boehringer Ingelheim Investigational Site 506
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kyoto : Boehringer Ingelheim Investigational Site 507
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kyoto : Boehringer Ingelheim Investigational Site 511
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kyoto : Boehringer Ingelheim Investigational Site 515
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kyoto : Boehringer Ingelheim Investigational Site 516
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Kyoto : Boehringer Ingelheim Investigational Site 517
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Machida : Boehringer Ingelheim Investigational Site 269
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Maebashi : Boehringer Ingelheim Investigational Site 146
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Maebashi : Boehringer Ingelheim Investigational Site 147
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Maebashi : Boehringer Ingelheim Investigational Site 148
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Maebashi : Boehringer Ingelheim Investigational Site 149
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Maebashi : Boehringer Ingelheim Investigational Site 150
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Maiduru : Boehringer Ingelheim Investigational Site 523
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Marugame : Boehringer Ingelheim Investigational Site 726
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Matsubara : Boehringer Ingelheim Investigational Site 543
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Matsudo : Boehringer Ingelheim Investigational Site 203
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Matsudo : Boehringer Ingelheim Investigational Site 202
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Matsue : Boehringer Ingelheim Investigational Site 662
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Matsumoto : Boehringer Ingelheim Investigational Site 399
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Matsumoto : Boehringer Ingelheim Investigational Site 400
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Matsumoto : Boehringer Ingelheim Investigational Site 398
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Matsuyama : Boehringer Ingelheim Investigational Site 738
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Matsuyama : Boehringer Ingelheim Investigational Site 741
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Matsuyama : Boehringer Ingelheim Investigational Site 739
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Matsuyama : Boehringer Ingelheim Investigational Site 740
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Matsuzaka : Boehringer Ingelheim Investigational Site 489
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Meguro-Ku : Boehringer Ingelheim Investigational Site 297
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Meguro-Ku : Boehringer Ingelheim Investigational Site 298
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Meguro-Ku : Boehringer Ingelheim Investigational Site 299
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Meguro-Ku : Boehringer Ingelheim Investigational Site 300
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Midori : Boehringer Ingelheim Investigational Site 140
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Minamata : Boehringer Ingelheim Investigational Site 823
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Minami aizu : Boehringer Ingelheim Investigational Site 96
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Minato-ku : Boehringer Ingelheim Investigational Site 230
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Minato-ku : Boehringer Ingelheim Investigational Site 232
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Minato-ku : Boehringer Ingelheim Investigational Site 231
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Minato-ku : Boehringer Ingelheim Investigational Site 233
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Mine : Boehringer Ingelheim Investigational Site 714
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Misawa : Boehringer Ingelheim Investigational Site 37
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Mishima : Boehringer Ingelheim Investigational Site 427
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Mishima : Boehringer Ingelheim Investigational Site 426
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Mita : Boehringer Ingelheim Investigational Site 603
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Mitaka : Boehringer Ingelheim Investigational Site 236
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Mitaka : Boehringer Ingelheim Investigational Site 237
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Mito : Boehringer Ingelheim Investigational Site 117
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Mito : Boehringer Ingelheim Investigational Site 115
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Mito : Boehringer Ingelheim Investigational Site 116
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Miyako : Boehringer Ingelheim Investigational Site 45
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Miyako : Boehringer Ingelheim Investigational Site 46
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Miyakonojo : Boehringer Ingelheim Investigational Site 842
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Miyazaki : Boehringer Ingelheim Investigational Site 839
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Miyazaki : Boehringer Ingelheim Investigational Site 840
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Miyazaki : Boehringer Ingelheim Investigational Site 841
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Miyoshi : Boehringer Ingelheim Investigational Site 689
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Mobara : Boehringer Ingelheim Investigational Site 216
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Moka : Boehringer Ingelheim Investigational Site 135
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Moka : Boehringer Ingelheim Investigational Site 134
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Moriguchi : Boehringer Ingelheim Investigational Site 542
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Morioka : Boehringer Ingelheim Investigational Site 47
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Morioka : Boehringer Ingelheim Investigational Site 48
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Moriya : Boehringer Ingelheim Investigational Site 111
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Munakata : Boehringer Ingelheim Investigational Site 765
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Murakami : Boehringer Ingelheim Investigational Site 361
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Murayama : Boehringer Ingelheim Investigational Site 271
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Muroto : Boehringer Ingelheim Investigational Site 753
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Musashino : Boehringer Ingelheim Investigational Site 286
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Mutsu : Boehringer Ingelheim Investigational Site 32
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Myoko : Boehringer Ingelheim Investigational Site 364
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nabari : Boehringer Ingelheim Investigational Site 492
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nagahama : Boehringer Ingelheim Investigational Site 498
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nagai : Boehringer Ingelheim Investigational Site 82
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nagano : Boehringer Ingelheim Investigational Site 408
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nagano : Boehringer Ingelheim Investigational Site 409
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nagaoka : Boehringer Ingelheim Investigational Site 362
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nagaoka : Boehringer Ingelheim Investigational Site 363
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nagaoka : Boehringer Ingelheim Investigational Site 521
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nagasaki : Boehringer Ingelheim Investigational Site 807
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nagasaki : Boehringer Ingelheim Investigational Site 808
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nagasaki : Boehringer Ingelheim Investigational Site 806
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nagasaki : Boehringer Ingelheim Investigational Site 809
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nago : Boehringer Ingelheim Investigational Site 860
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nagoya : Boehringer Ingelheim Investigational Site 472
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nagoya : Boehringer Ingelheim Investigational Site 474
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nagoya : Boehringer Ingelheim Investigational Site 475
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nagoya : Boehringer Ingelheim Investigational Site 476
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nagoya : Boehringer Ingelheim Investigational Site 477
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nagoya : Boehringer Ingelheim Investigational Site 478
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nagoya : Boehringer Ingelheim Investigational Site 479
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nagoya : Boehringer Ingelheim Investigational Site 482
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nagoya : Boehringer Ingelheim Investigational Site 484
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nagoya : Boehringer Ingelheim Investigational Site 471
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nagoya : Boehringer Ingelheim Investigational Site 473
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nagoya : Boehringer Ingelheim Investigational Site 480
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nagoya : Boehringer Ingelheim Investigational Site 481
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nagoya : Boehringer Ingelheim Investigational Site 483
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Naha : Boehringer Ingelheim Investigational Site 858
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nakagami : Boehringer Ingelheim Investigational Site 857
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nakano-Ku : Boehringer Ingelheim Investigational Site 267
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nakano-Ku : Boehringer Ingelheim Investigational Site 268
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nakatado : Boehringer Ingelheim Investigational Site 733
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nakatado : Boehringer Ingelheim Investigational Site 734
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nakatsu : Boehringer Ingelheim Investigational Site 833
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nakatsugawa : Boehringer Ingelheim Investigational Site 421
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nanao : Boehringer Ingelheim Investigational Site 379
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nangoku : Boehringer Ingelheim Investigational Site 755
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nantan : Boehringer Ingelheim Investigational Site 522
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nara : Boehringer Ingelheim Investigational Site 644
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Narita : Boehringer Ingelheim Investigational Site 204
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Narita : Boehringer Ingelheim Investigational Site 205
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Naruto : Boehringer Ingelheim Investigational Site 724
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nasu shiobara : Boehringer Ingelheim Investigational Site 138
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nasu shiobara : Boehringer Ingelheim Investigational Site 139
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nerima-Ku : Boehringer Ingelheim Investigational Site 302
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nerima-Ku : Boehringer Ingelheim Investigational Site 303
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nerima-Ku : Boehringer Ingelheim Investigational Site 304
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Neyagawa : Boehringer Ingelheim Investigational Site 545
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Neyagawa : Boehringer Ingelheim Investigational Site 546
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Neyagawa : Boehringer Ingelheim Investigational Site 544
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nihonmatsu : Boehringer Ingelheim Investigational Site 97
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Niigata : Boehringer Ingelheim Investigational Site 355
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Niigata : Boehringer Ingelheim Investigational Site 356
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Niigata : Boehringer Ingelheim Investigational Site 357
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Niigata : Boehringer Ingelheim Investigational Site 358
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Niigata : Boehringer Ingelheim Investigational Site 353
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Niigata : Boehringer Ingelheim Investigational Site 354
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Niigata : Boehringer Ingelheim Investigational Site 359
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Niihama : Boehringer Ingelheim Investigational Site 743
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Niihama : Boehringer Ingelheim Investigational Site 742
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Niihama : Boehringer Ingelheim Investigational Site 744
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ninohe : Boehringer Ingelheim Investigational Site 49
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nishi Matsuura : Boehringer Ingelheim Investigational Site 798
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nishinomiya : Boehringer Ingelheim Investigational Site 619
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nishinomiya : Boehringer Ingelheim Investigational Site 617
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nishinomiya : Boehringer Ingelheim Investigational Site 618
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nishio : Boehringer Ingelheim Investigational Site 461
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nishi-tokyo : Boehringer Ingelheim Investigational Site 256
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nishiwaki : Boehringer Ingelheim Investigational Site 620
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nishiyachiyo : Boehringer Ingelheim Investigational Site 392
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nissin : Boehringer Ingelheim Investigational Site 463
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nita : Boehringer Ingelheim Investigational Site 663
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nobeoka : Boehringer Ingelheim Investigational Site 838
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Noda : Boehringer Ingelheim Investigational Site 218
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Noda : Boehringer Ingelheim Investigational Site 217
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Noshiro : Boehringer Ingelheim Investigational Site 77
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Numazu : Boehringer Ingelheim Investigational Site 428
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Numazu : Boehringer Ingelheim Investigational Site 429
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Nyu : Boehringer Ingelheim Investigational Site 383
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Obihiro : Boehringer Ingelheim Investigational Site 23
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Obihiro : Boehringer Ingelheim Investigational Site 22
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Obu : Boehringer Ingelheim Investigational Site 462
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Odate : Boehringer Ingelheim Investigational Site 73
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Odawara : Boehringer Ingelheim Investigational Site 326
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Oga : Boehringer Ingelheim Investigational Site 75
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ogori : Boehringer Ingelheim Investigational Site 767
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ohgaki : Boehringer Ingelheim Investigational Site 420
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ohmihachiman : Boehringer Ingelheim Investigational Site 494
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ohmihachiman : Boehringer Ingelheim Investigational Site 495
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ohsu : Boehringer Ingelheim Investigational Site 745
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Oita : Boehringer Ingelheim Investigational Site 829
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Oita : Boehringer Ingelheim Investigational Site 830
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Oita : Boehringer Ingelheim Investigational Site 831
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Oita : Boehringer Ingelheim Investigational Site 832
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ojiya : Boehringer Ingelheim Investigational Site 350
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Okayama : Boehringer Ingelheim Investigational Site 667
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Okayama : Boehringer Ingelheim Investigational Site 669
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Okayama : Boehringer Ingelheim Investigational Site 670
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Okayama : Boehringer Ingelheim Investigational Site 668
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Okayama : Boehringer Ingelheim Investigational Site 671
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Okazaki : Boehringer Ingelheim Investigational Site 453
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Okinawa : Boehringer Ingelheim Investigational Site 856
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Omura : Boehringer Ingelheim Investigational Site 805
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Omuta : Boehringer Ingelheim Investigational Site 769
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Omuta : Boehringer Ingelheim Investigational Site 770
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Onga : Boehringer Ingelheim Investigational Site 757
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Onga : Boehringer Ingelheim Investigational Site 758
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Onomichi : Boehringer Ingelheim Investigational Site 694
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Onomichi : Boehringer Ingelheim Investigational Site 695
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ora : Boehringer Ingelheim Investigational Site 156
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ora : Boehringer Ingelheim Investigational Site 155
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Osaka : Boehringer Ingelheim Investigational Site 553
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Osaka : Boehringer Ingelheim Investigational Site 554
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Osaka : Boehringer Ingelheim Investigational Site 558
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Osaka : Boehringer Ingelheim Investigational Site 560
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Osaka : Boehringer Ingelheim Investigational Site 561
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Osaka : Boehringer Ingelheim Investigational Site 563
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Osaka : Boehringer Ingelheim Investigational Site 568
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Osaka : Boehringer Ingelheim Investigational Site 571
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Osaka : Boehringer Ingelheim Investigational Site 573
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Osaka : Boehringer Ingelheim Investigational Site 576
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Osaka : Boehringer Ingelheim Investigational Site 577
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Osaka : Boehringer Ingelheim Investigational Site 578
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Osaka : Boehringer Ingelheim Investigational Site 555
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Osaka : Boehringer Ingelheim Investigational Site 556
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Osaka : Boehringer Ingelheim Investigational Site 557
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Osaka : Boehringer Ingelheim Investigational Site 559
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Osaka : Boehringer Ingelheim Investigational Site 562
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Osaka : Boehringer Ingelheim Investigational Site 564
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Osaka : Boehringer Ingelheim Investigational Site 565
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Osaka : Boehringer Ingelheim Investigational Site 566
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Osaka : Boehringer Ingelheim Investigational Site 567
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Osaka : Boehringer Ingelheim Investigational Site 569
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Osaka : Boehringer Ingelheim Investigational Site 570
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Osaka : Boehringer Ingelheim Investigational Site 572
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Osaka : Boehringer Ingelheim Investigational Site 574
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Osaka : Boehringer Ingelheim Investigational Site 575
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Osaka : Boehringer Ingelheim Investigational Site 579
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Osaka : Boehringer Ingelheim Investigational Site 580
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Osaka : Boehringer Ingelheim Investigational Site 581
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Oshu : Boehringer Ingelheim Investigational Site 44
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Oshu : Boehringer Ingelheim Investigational Site 43
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ota : Boehringer Ingelheim Investigational Site 664
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ota : Boehringer Ingelheim Investigational Site 151
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ota : Boehringer Ingelheim Investigational Site 152
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ota-Ku : Boehringer Ingelheim Investigational Site 265
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ota-Ku : Boehringer Ingelheim Investigational Site 263
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ota-Ku : Boehringer Ingelheim Investigational Site 264
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Otaru : Boehringer Ingelheim Investigational Site 21
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Otsu : Boehringer Ingelheim Investigational Site 497
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Rumoi : Boehringer Ingelheim Investigational Site 31
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ryugasaki : Boehringer Ingelheim Investigational Site 123
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Saeki : Boehringer Ingelheim Investigational Site 828
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Saeki : Boehringer Ingelheim Investigational Site 827
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Saga : Boehringer Ingelheim Investigational Site 795
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Saga : Boehringer Ingelheim Investigational Site 797
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Saga : Boehringer Ingelheim Investigational Site 796
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sagae : Boehringer Ingelheim Investigational Site 79
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sagamihara : Boehringer Ingelheim Investigational Site 336
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sagamihara : Boehringer Ingelheim Investigational Site 337
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sagamihara : Boehringer Ingelheim Investigational Site 338
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sagamihara : Boehringer Ingelheim Investigational Site 339
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Saitama : Boehringer Ingelheim Investigational Site 157
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Saitama : Boehringer Ingelheim Investigational Site 158
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Saitama : Boehringer Ingelheim Investigational Site 161
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Saitama : Boehringer Ingelheim Investigational Site 163
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Saitama : Boehringer Ingelheim Investigational Site 164
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Saitama : Boehringer Ingelheim Investigational Site 159
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Saitama : Boehringer Ingelheim Investigational Site 160
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Saitama : Boehringer Ingelheim Investigational Site 162
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sakai : Boehringer Ingelheim Investigational Site 535
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sakai : Boehringer Ingelheim Investigational Site 536
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sakai : Boehringer Ingelheim Investigational Site 537
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sakai : Boehringer Ingelheim Investigational Site 539
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sakai : Boehringer Ingelheim Investigational Site 538
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sakai : Boehringer Ingelheim Investigational Site 540
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sakai : Boehringer Ingelheim Investigational Site 541
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sakaide : Boehringer Ingelheim Investigational Site 732
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sakata : Boehringer Ingelheim Investigational Site 81
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Saku : Boehringer Ingelheim Investigational Site 397
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sakura : Boehringer Ingelheim Investigational Site 197
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sakura : Boehringer Ingelheim Investigational Site 124
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sanjo : Boehringer Ingelheim Investigational Site 347
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sano : Boehringer Ingelheim Investigational Site 130
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sano : Boehringer Ingelheim Investigational Site 129
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sanuki : Boehringer Ingelheim Investigational Site 725
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sanyo Onoda : Boehringer Ingelheim Investigational Site 710
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sapporo : Boehringer Ingelheim Investigational Site 13
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sapporo : Boehringer Ingelheim Investigational Site 12
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sapporo : Boehringer Ingelheim Investigational Site 11
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sapporo : Boehringer Ingelheim Investigational Site 19
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sapporo : Boehringer Ingelheim Investigational Site 14
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sapporo : Boehringer Ingelheim Investigational Site 15
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sapporo : Boehringer Ingelheim Investigational Site 16
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sapporo : Boehringer Ingelheim Investigational Site 17
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sapporo : Boehringer Ingelheim Investigational Site 18
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sapporo : Boehringer Ingelheim Investigational Site 10
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sapporo : Boehringer Ingelheim Investigational Site 20
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sasebo : Boehringer Ingelheim Investigational Site 802
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sasebo : Boehringer Ingelheim Investigational Site 803
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sashima : Boehringer Ingelheim Investigational Site 107
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sayama : Boehringer Ingelheim Investigational Site 169
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sendai : Boehringer Ingelheim Investigational Site 56
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sendai : Boehringer Ingelheim Investigational Site 57
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sendai : Boehringer Ingelheim Investigational Site 62
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sendai : Boehringer Ingelheim Investigational Site 61
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sendai : Boehringer Ingelheim Investigational Site 63
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sendai : Boehringer Ingelheim Investigational Site 55
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sendai : Boehringer Ingelheim Investigational Site 60
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sendai : Boehringer Ingelheim Investigational Site 59
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sendai : Boehringer Ingelheim Investigational Site 58
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Setagaya-Ku : Boehringer Ingelheim Investigational Site 255
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shibata : Boehringer Ingelheim Investigational Site 54
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shibata : Boehringer Ingelheim Investigational Site 360
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shibukawa : Boehringer Ingelheim Investigational Site 145
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shibuya-ku : Boehringer Ingelheim Investigational Site 238
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shikoku Chuo : Boehringer Ingelheim Investigational Site 737
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shimabara : Boehringer Ingelheim Investigational Site 810
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shimada : Boehringer Ingelheim Investigational Site 435
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shimonoseki : Boehringer Ingelheim Investigational Site 702
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shimonoseki : Boehringer Ingelheim Investigational Site 704
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shimonoseki : Boehringer Ingelheim Investigational Site 703
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shinagawa-ku : Boehringer Ingelheim Investigational Site 282
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shingu : Boehringer Ingelheim Investigational Site 647
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shinjuku-ku : Boehringer Ingelheim Investigational Site 250
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shinjuku-ku : Boehringer Ingelheim Investigational Site 243
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shinjuku-ku : Boehringer Ingelheim Investigational Site 247
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shinjuku-ku : Boehringer Ingelheim Investigational Site 249
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shinjuku-ku : Boehringer Ingelheim Investigational Site 242
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shinjuku-ku : Boehringer Ingelheim Investigational Site 244
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shinjuku-ku : Boehringer Ingelheim Investigational Site 245
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shinjuku-ku : Boehringer Ingelheim Investigational Site 246
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shinjuku-ku : Boehringer Ingelheim Investigational Site 248
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shiojiri : Boehringer Ingelheim Investigational Site 396
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shiraishi : Boehringer Ingelheim Investigational Site 67
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shirakawa : Boehringer Ingelheim Investigational Site 98
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shiroi : Boehringer Ingelheim Investigational Site 213
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shizuoka : Boehringer Ingelheim Investigational Site 430
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shizuoka : Boehringer Ingelheim Investigational Site 432
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shizuoka : Boehringer Ingelheim Investigational Site 433
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shizuoka : Boehringer Ingelheim Investigational Site 434
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shizuoka : Boehringer Ingelheim Investigational Site 431
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shobara : Boehringer Ingelheim Investigational Site 690
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shunan : Boehringer Ingelheim Investigational Site 711
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Shunan : Boehringer Ingelheim Investigational Site 712
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Soka : Boehringer Ingelheim Investigational Site 180
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Soka : Boehringer Ingelheim Investigational Site 181
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Soka : Boehringer Ingelheim Investigational Site 182
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Soka : Boehringer Ingelheim Investigational Site 183
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Suginami-Ku : Boehringer Ingelheim Investigational Site 252
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Suginami-Ku : Boehringer Ingelheim Investigational Site 253
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Suginami-Ku : Boehringer Ingelheim Investigational Site 254
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Suginami-Ku : Boehringer Ingelheim Investigational Site 251
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Suita : Boehringer Ingelheim Investigational Site 550
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Suita : Boehringer Ingelheim Investigational Site 547
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Suita : Boehringer Ingelheim Investigational Site 548
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Suita : Boehringer Ingelheim Investigational Site 549
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sukagawa : Boehringer Ingelheim Investigational Site 95
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sumida-ku : Boehringer Ingelheim Investigational Site 295
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sumida-ku : Boehringer Ingelheim Investigational Site 296
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Sumoto : Boehringer Ingelheim Investigational Site 604
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Suwa : Boehringer Ingelheim Investigational Site 404
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Suwa : Boehringer Ingelheim Investigational Site 405
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Suzaka : Boehringer Ingelheim Investigational Site 406
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Suzaki : Boehringer Ingelheim Investigational Site 754
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Suzuka : Boehringer Ingelheim Investigational Site 493
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tachikawa : Boehringer Ingelheim Investigational Site 301
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Taisen : Boehringer Ingelheim Investigational Site 74
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tajimi : Boehringer Ingelheim Investigational Site 419
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Takahashi : Boehringer Ingelheim Investigational Site 673
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Takamatsu : Boehringer Ingelheim Investigational Site 727
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Takamatsu : Boehringer Ingelheim Investigational Site 728
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Takamatsu : Boehringer Ingelheim Investigational Site 730
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Takamatsu : Boehringer Ingelheim Investigational Site 731
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Takamatsu : Boehringer Ingelheim Investigational Site 729
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Takaoka : Boehringer Ingelheim Investigational Site 367
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Takaoka : Boehringer Ingelheim Investigational Site 365
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Takaoka : Boehringer Ingelheim Investigational Site 366
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Takaraduka : Boehringer Ingelheim Investigational Site 635
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Takasaki : Boehringer Ingelheim Investigational Site 143
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Takasaki : Boehringer Ingelheim Investigational Site 144
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Takatsuki : Boehringer Ingelheim Investigational Site 533
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Takatsuki : Boehringer Ingelheim Investigational Site 534
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Takayama : Boehringer Ingelheim Investigational Site 417
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Takehara : Boehringer Ingelheim Investigational Site 691
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Takehara : Boehringer Ingelheim Investigational Site 692
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Takeo : Boehringer Ingelheim Investigational Site 800
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Taki : Boehringer Ingelheim Investigational Site 490
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Taku : Boehringer Ingelheim Investigational Site 799
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tama : Boehringer Ingelheim Investigational Site 261
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tama : Boehringer Ingelheim Investigational Site 262
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tamana : Boehringer Ingelheim Investigational Site 813
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tanabe : Boehringer Ingelheim Investigational Site 648
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tarumi : Boehringer Ingelheim Investigational Site 853
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tateyama : Boehringer Ingelheim Investigational Site 195
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tatsuno : Boehringer Ingelheim Investigational Site 598
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tenri : Boehringer Ingelheim Investigational Site 643
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tnami : Boehringer Ingelheim Investigational Site 368
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tochigi : Boehringer Ingelheim Investigational Site 137
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tokamacho : Boehringer Ingelheim Investigational Site 349
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tokorozawa : Boehringer Ingelheim Investigational Site 173
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tokorozawa : Boehringer Ingelheim Investigational Site 174
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tokushima : Boehringer Ingelheim Investigational Site 719
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tokushima : Boehringer Ingelheim Investigational Site 720
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tokushima : Boehringer Ingelheim Investigational Site 721
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tokushima : Boehringer Ingelheim Investigational Site 722
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tomakomai : Boehringer Ingelheim Investigational Site 24
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tomigusuku : Boehringer Ingelheim Investigational Site 859
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tomioka : Boehringer Ingelheim Investigational Site 153
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tondabayashi : Boehringer Ingelheim Investigational Site 588
Post-Marketing Surveillance of Prazaxa on the Long-term Use
To-on : Boehringer Ingelheim Investigational Site 746
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Toshima-Ku : Boehringer Ingelheim Investigational Site 292
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Toshima-Ku : Boehringer Ingelheim Investigational Site 293
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tottori : Boehringer Ingelheim Investigational Site 655
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tottori : Boehringer Ingelheim Investigational Site 654
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Toyama : Boehringer Ingelheim Investigational Site 372
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Toyama : Boehringer Ingelheim Investigational Site 370
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Toyama : Boehringer Ingelheim Investigational Site 371
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Toyoda : Boehringer Ingelheim Investigational Site 468
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Toyoda : Boehringer Ingelheim Investigational Site 469
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Toyohashi : Boehringer Ingelheim Investigational Site 466
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Toyokawa : Boehringer Ingelheim Investigational Site 467
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Toyonaka : Boehringer Ingelheim Investigational Site 591
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Toyonaka : Boehringer Ingelheim Investigational Site 589
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Toyonaka : Boehringer Ingelheim Investigational Site 590
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Toyooka : Boehringer Ingelheim Investigational Site 636
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tsu : Boehringer Ingelheim Investigational Site 491
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tsubame : Boehringer Ingelheim Investigational Site 345
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tsuchiura : Boehringer Ingelheim Investigational Site 120
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tsukuba : Boehringer Ingelheim Investigational Site 103
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tsukuba : Boehringer Ingelheim Investigational Site 104
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tsuruoka : Boehringer Ingelheim Investigational Site 83
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tsushima : Boehringer Ingelheim Investigational Site 804
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Tsuyama : Boehringer Ingelheim Investigational Site 677
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ube : Boehringer Ingelheim Investigational Site 700
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ube : Boehringer Ingelheim Investigational Site 701
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ueda : Boehringer Ingelheim Investigational Site 403
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Uji : Boehringer Ingelheim Investigational Site 501
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Uji : Boehringer Ingelheim Investigational Site 502
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Urasoe : Boehringer Ingelheim Investigational Site 855
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Urayasu : Boehringer Ingelheim Investigational Site 194
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Usa : Boehringer Ingelheim Investigational Site 638
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Ushiku : Boehringer Ingelheim Investigational Site 108
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Utsunomiya : Boehringer Ingelheim Investigational Site 125
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Utsunomiya : Boehringer Ingelheim Investigational Site 126
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Utsunomiya : Boehringer Ingelheim Investigational Site 127
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Utsunomiya : Boehringer Ingelheim Investigational Site 128
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Uwajima : Boehringer Ingelheim Investigational Site 736
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Wakayama : Boehringer Ingelheim Investigational Site 650
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Wakayama : Boehringer Ingelheim Investigational Site 651
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Wakayama : Boehringer Ingelheim Investigational Site 652
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Wakayama : Boehringer Ingelheim Investigational Site 653
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yachimata : Boehringer Ingelheim Investigational Site 214
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yamaagata : Boehringer Ingelheim Investigational Site 418
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yamaga : Boehringer Ingelheim Investigational Site 821
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yamagata : Boehringer Ingelheim Investigational Site 80
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yamaguchi : Boehringer Ingelheim Investigational Site 708
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yamaguchi : Boehringer Ingelheim Investigational Site 709
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yamanashi : Boehringer Ingelheim Investigational Site 390
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yamanashi : Boehringer Ingelheim Investigational Site 391
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yamato : Boehringer Ingelheim Investigational Site 341
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yamatokoriyama : Boehringer Ingelheim Investigational Site 641
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yamatotakada : Boehringer Ingelheim Investigational Site 642
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yame : Boehringer Ingelheim Investigational Site 773
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yanai : Boehringer Ingelheim Investigational Site 716
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yao : Boehringer Ingelheim Investigational Site 586
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yao : Boehringer Ingelheim Investigational Site 587
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yashiro : Boehringer Ingelheim Investigational Site 825
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yashiro : Boehringer Ingelheim Investigational Site 826
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yatomi : Boehringer Ingelheim Investigational Site 485
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yawatahama : Boehringer Ingelheim Investigational Site 747
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yokkaichi : Boehringer Ingelheim Investigational Site 487
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yokkaichi : Boehringer Ingelheim Investigational Site 488
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yokohama : Boehringer Ingelheim Investigational Site 310
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yokohama : Boehringer Ingelheim Investigational Site 312
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yokohama : Boehringer Ingelheim Investigational Site 313
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yokohama : Boehringer Ingelheim Investigational Site 314
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yokohama : Boehringer Ingelheim Investigational Site 319
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yokohama : Boehringer Ingelheim Investigational Site 322
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yokohama : Boehringer Ingelheim Investigational Site 320
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yokohama : Boehringer Ingelheim Investigational Site 321
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yokohama : Boehringer Ingelheim Investigational Site 311
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yokohama : Boehringer Ingelheim Investigational Site 315
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yokohama : Boehringer Ingelheim Investigational Site 316
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yokohama : Boehringer Ingelheim Investigational Site 317
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yokohama : Boehringer Ingelheim Investigational Site 318
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yokohama : Boehringer Ingelheim Investigational Site 308
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yokohama : Boehringer Ingelheim Investigational Site 309
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yokosuka : Boehringer Ingelheim Investigational Site 307
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yokosuka : Boehringer Ingelheim Investigational Site 306
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yokote : Boehringer Ingelheim Investigational Site 68
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yokote : Boehringer Ingelheim Investigational Site 69
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yonago : Boehringer Ingelheim Investigational Site 656
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yonago : Boehringer Ingelheim Investigational Site 657
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yonezawa : Boehringer Ingelheim Investigational Site 87
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yotsukaido : Boehringer Ingelheim Investigational Site 198
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yuki : Boehringer Ingelheim Investigational Site 110
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yuki : Boehringer Ingelheim Investigational Site 109
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Yuzawa : Boehringer Ingelheim Investigational Site 76
Post-Marketing Surveillance of Prazaxa on the Long-term Use
Korea, Republic of
Seoul : MSD Korea Ltd.
A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM2)
Seoul : Korea University Anam Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Seoul : Asan Medical Center
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Seoul : MSD Korea Ltd.
International Registry on Cardioversion of Atrial Fibrillation (MK-6621-051)
Seoul : Republic of Korea University Medical Center
Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation
View More »
Soeul : Yonsei University Severance Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Netherlands
Almelo : Ziekenhuisgroep Twente
Routine Versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure
Amsterdam : Lucas Andreas Ziekenhuis
Optimal Sensing in Atrial Tachyarrhythmia's Study
Amsterdam : Onze Lieve Vrouwe Gasthuis
Routine Versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure
Arnhem : Rijnstate Ziekenhuis
Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)
Arnhem/Velp : Hospital Rijnstate
Routine Versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure
View More »
Blaricum : Ter Gooi Hospital
Routine Versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure
Breda : Amhia Hospital
Routine Versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure
Deventer : Deventer Hospital
Routine Versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure
Goes : Oosterscheldeziekenhuis
Routine Versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure
Groningen : University Hospital
Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)
Groningen : University Medical Center Groningen
Routine Versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure
Groningen : Martini Hospital
Routine Versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure
Haarlem : Kennemer Gasthuis
Routine Versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure
Heerlen : Atrium Medisch Centrum
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Leiden : University Medical Center
Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)
Maastricht : Medical University Center Maastricht
Routine Versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure
Nieuwegein : St. Antonius Hospital Nieuwegein
Ablation or Surgery for Atrial Fibrillation (AF) Treatment
Nieuwegein : Antonius Ziekenhuis
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
Nieuwegein : St. Antonius Ziekenhuis
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Nijmegen : University Medical Center Nijmegen
Routine Versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure
Rotterdam : Erasmus Medical Center
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
Winschoten : Ommelander Hospital
Routine Versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure
Zwolle : Isala Klinieken
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
Zwolle : Isala Klinieken
Surgical or Catheter Ablation of Lone Atrial Fibrillation (AF) Patients
Russian Federation
Novosibirsk : State Research Institute of Circulation Pathology
Catheter Ablation for Recently Diagnosed Paroxysmal Atrial Fibrillation
Novosibirsk : Research Institute of Circulation of Pathology
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Tomsk : Scientific Research Institute of Cardiology of Ministry of Health of Russian Foundation
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Slovakia
Bratislava : NUSCH, a.s. Bratislava
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Kosice : VUSCH Kosice
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Spain
Barcelona : Hospital Clinic Barcelona
Ablation or Surgery for Atrial Fibrillation (AF) Treatment
Barcelona : Hospital Clínic i Provincial de Barcelona, Servicio de Cardiología-Sección de Arritmias
Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion
Barcelona : Hospital de Sant Pau
Study of Ablation Versus antiaRrhythmic Drugs in Persistent Atrial Fibrillation
Barcelona : Hospital Clinic Universitari
Study of Ablation Versus antiaRrhythmic Drugs in Persistent Atrial Fibrillation
Bilbao : Hospital de Cruces
Study of Ablation Versus antiaRrhythmic Drugs in Persistent Atrial Fibrillation
View More »
Madrid : Hospital Clínico San Carlos
Study of Ablation Versus antiaRrhythmic Drugs in Persistent Atrial Fibrillation
Madrid : Hospital Gregorio Marañon
Study of Ablation Versus antiaRrhythmic Drugs in Persistent Atrial Fibrillation
Madrid : Hospital Ramón y Cajal
Study of Ablation Versus antiaRrhythmic Drugs in Persistent Atrial Fibrillation
Madrid : Clínica Puerta de Hierro
Study of Ablation Versus antiaRrhythmic Drugs in Persistent Atrial Fibrillation
Madrid : Hospital 12 de Octubre
Study of Ablation Versus antiaRrhythmic Drugs in Persistent Atrial Fibrillation
Majadahonda : Hospital Puerta de Hierro Majadahonda
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Sweden
Lund : University Hospital Lund
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Örebro : Örebro University Hospital
Totally Endoscopic Ablation of Atrial Fibrillation
Stockholm : Karolinska University Hospital Stockholm
Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)
Switzerland
Geneve : HUG Hopitaux Universitaires de Genève
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
Lugano : Cardiocentro Ticino
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
Turkey
United Kingdom
Birmingham :
BIOTRONIK IMPACT Study
Cambridge : Papworth Hospital NHS Foundation Trust
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Chertsey : St. Peter's Hospital
Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)
Eastbourne : Eastbourne General Hospital
Pacemaker Holter Assessment of the Effect of BMS-914392 on Atrial Fibrillation Burden
Glasgow : Golden Jubilee Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
View More »
London : Saint Thomas Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
London : Saint Bartholomew's Hospital
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
London : Saint George's Hospital Medical School
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
London : St. Mary's Hospital Imperial College Healthcare NHS Trust
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
London : The Heart Hospital
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
London : St. Bartholomew's Hospital
Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation
United States
Washington : Otsuka Investigational Site
Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation
Washington, D.C. : George Washington University Medical Faculty Associates
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
